Pressure BioSciences (PBIO) 10-K 5 Apr 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-38185
Entity Registrant Name	PRESSURE BIOSCIENCES, INC.
Entity Central Index Key	0000830656
Entity Tax Identification Number	04-2652826
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	14 Norfolk Avenue
Entity Address, City or Town	South Easton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02375
City Area Code	508
Local Phone Number	230-1828
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 13,334,762
Entity Common Stock, Shares Outstanding		8,712,494
Auditor Firm ID	206
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 132,311	$ 18,540
Accounts receivable	154,746	131,228
Inventories, net of $342,496 reserve at December 31, 2021 and December 31, 2020	1,147,554	592,767
Prepaid expenses and other current assets	422,617	314,936
Total current assets	1,857,228	1,057,471
Investment in equity securities	59,976	517,001
Property and equipment, net	115,846	16,490
Right of use asset leases	395,565	221,432
Intangible assets, net	403,846	490,385
TOTAL ASSETS	2,832,461	2,302,779
CURRENT LIABILITIES
Accounts payable	527,924	771,945
Accrued employee compensation	117,680	417,578
Accrued professional fees and other	1,955,672	2,037,806
Other current liabilities	7,757,217	6,330,722
Deferred revenue	37,124	47,328
Convertible debt, net of unamortized discounts of $1,536,649 and $3,948,167, respectively	12,839,813	7,545,670
Other debt	1,256,840	1,135,469
Operating lease liability	132,996	65,193
Other related party debt		166,000
Total current liabilities	24,625,266	18,517,711
LONG TERM LIABILITIES
Long term debt	150,000	527,039
Operating lease liability – long term	262,569	156,239
Deferred revenue	3,587	19,382
TOTAL LIABILITIES	25,041,422	19,220,371
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 9,120,526 and 4,168,324 shares issued and outstanding on December 31, 2021 and 2020 respectively	91,206	41,683
Warrants to acquire common stock	31,715,154	29,192,471
Additional paid-in capital	64,261,048	50,312,968
Accumulated deficit	(118,277,468)	(96,465,807)
Total stockholders’ deficit	(22,208,961)	(16,917,592)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	2,832,461	2,302,779
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock	806	806
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock	35	35
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock	68	68
Series AA Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock	$ 87	$ 81

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory Valuation Reserves	$ 342,496	$ 342,496
Debt Instrument, Unamortized Discount	$ 1,536,649	$ 3,948,167
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	9,120,526	4,168,324
Common Stock, Shares, Outstanding	9,120,526	4,168,324
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	850	850
Preferred stock, shares issued	300	300
Preferred stock, shares outstanding	300	300
Preferred stock, liquidation preference value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	80,570	80,570
Preferred stock, shares outstanding	80,570	80,570
Series H Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	21	21
Preferred stock, shares issued	21	21
Preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,250	6,250
Preferred stock, shares issued	3,458	3,458
Preferred stock, shares outstanding	3,458	3,458
Series K Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000	15,000
Preferred stock, shares issued	6,880	6,880
Preferred stock, shares outstanding	6,880	6,880
Series AA Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	8,649	8,043
Preferred stock, shares outstanding	8,649	8,043

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Products, services, other	$ 2,002,365	$ 1,220,591
Costs and expenses:
Cost of products and services	942,383	582,854
Research and development	1,101,509	1,143,420
Selling and marketing	324,728	649,783
General and administrative	3,818,892	3,430,321
Total operating costs and expenses	6,187,512	5,806,378
Operating loss	(4,185,147)	(4,585,787)
Other (expense) income:
Interest expense, net	(14,450,241)	(8,344,236)
Unrealized (loss) gain on investment in equity securities	(457,025)	500,358
Loss on extinguishment of liabilities	(1,061,073)	(3,575,878)
Total other expense	(15,968,339)	(11,419,756)
Net loss	(20,153,486)	(16,005,543)
Deemed dividends on beneficial conversion feature	(873,798)	(61,180)
Preferred stock dividends	(1,658,175)	(1,517,987)
Net loss attributable to common shareholders	$ (22,685,459)	$ (17,584,710)
Net loss per share - basic and diluted	$ (3.42)	$ (5.32)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	6,636,523	3,304,187

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholder's Deficit - USD ($)	Series D Convertible Preferred Stock [Member]Preferred Stock [Member]	Series G Convertible Preferred Stock [Member]Preferred Stock [Member]	Series H Convertible Preferred Stock [Member]Preferred Stock [Member]	Series H2 Convertible Preferred Stock [Member]Preferred Stock [Member]	Series J Convertible Preferred Stock [Member]Preferred Stock [Member]	Series K Convertible Preferred Stock [Member]Preferred Stock [Member]	Series AA Convertible Preferred Stock [Member]Preferred Stock [Member]	Series AA Convertible Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 3	$ 806	$ 100		$ 35	$ 68	$ 80		$ 25,496	$ 22,599,177	$ 44,261,105		$ (78,942,277)	$ (12,055,407)
Balance, shares at Dec. 31, 2019	300	80,570	10,000	21	3,458	6,880	7,939		2,549,620
Stock-based compensation											488,792			$ 488,792
Stock option exercise, shares
Warrant exercise shares
Beneficial conversion feature on debt											1,756,311			$ 1,756,311
Beneficial conversion option on convertible preferred stock											61,180			61,180
Deemed dividend-beneficial conversion feature											(61,180)			(61,180)
Preferred stock issued for debt settlement, shares
Common stock issued for debt settlement									$ 1,888		372,662			374,550
Common stock issued for debt settlement, shares									188,778
Conversion of debt and interest for common stock									$ 8,712		2,211,730			2,220,442
Conversion of debt and interest for common stock, shares									871,309
Conversion of debt into Series AA convertible preferred stock										38,783	71,217			110,000
Conversion of debt into Series AA convertible preferred stock, shares							44
Issuance of common stock for dividends paid-in-kind									$ 1,222		298,487			299,709
Issuance of common stock for dividends paid-in-kind, shares									122,135
Issuance of common stock for interest paid-in-kind									$ 1,345		253,914			255,259
Issuance of common stock for interest paid-in-kind, shares									134,482
Issuance of common stock for services									$ 768		178,309			179,077
Issuance of common stock for services, shares									76,800
Issuance of common stock to settle accrued liabilities									$ 665		127,190			127,855
Issuance of common stock to settle accrued liabilities, shares									66,500
Preferred Stock offering							$ 1			69,580	80,419			150,000
Preferred stock offering, shares							60
Series AA Preferred Stock dividend													(1,517,987)	(1,517,987)
Stock issued with debt, shares
Common stock issued with debt									$ 1,587		212,832			214,419
Common stock issued with debt, shares									158,700
Warrants issued for debt extension										1,282,560				1,282,560
Warrants issued with debt										4,863,959				4,863,959
Warrants issued for debt settlement										338,412				338,412
Net loss													(16,005,543)	(16,005,543)
Ending balance, value at Dec. 31, 2020	$ 3	$ 806	$ 100		$ 35	$ 68	$ 81		$ 41,683	29,192,471	50,312,968		(96,465,807)	(16,917,592)
Balance, shares at Dec. 31, 2020	300	80,570	10,000	21	3,458	6,880	8,043		4,168,324
Stock-based compensation											254,615			254,615
Stock option exercise									$ 214		14,559			$ 14,773
Stock option exercise, shares									21,411	187,500				208,911
Issuance of common stock for non-cash warrant exercise									$ 363	$ (343,201)	342,838
Warrant exercise shares									36,290
Beneficial conversion feature on debt											1,320,331			1,320,331
Beneficial conversion option on convertible preferred stock											873,798			873,798
Deemed dividend on convertible preferred stock											(873,798)			(873,798)
Preferred stock issued for debt settlement							$ 2			245,635	277,617			523,254
Preferred stock issued for debt settlement, shares							200
Common stock issued for debt settlement							$ 184,274	$ 184,274						$ 6,665,656
Common stock issued for debt settlement, shares							82,373	82,373						2,883,282
Conversion of debt and interest for common stock								$ 2,989,990	$ 11,960		2,978,030			$ 2,989,990
Conversion of debt and interest for common stock, shares									1,195,996					1,195,996
Issuance of common stock for dividends paid-in-kind									$ 823		183,451			$ 184,274
Issuance of common stock for dividends paid-in-kind, shares									82,373
Issuance of common stock for interest paid-in-kind									$ 28,835		6,636,821			6,665,656
Issuance of common stock for interest paid-in-kind, shares									2,883,282
Issuance of common stock for services									$ 3,332		791,230			$ 794,562
Issuance of common stock for services, shares									333,200					333,200
Preferred Stock offering							$ 4			509,130	505,866			$ 1,015,000
Preferred stock offering, shares							406
Series AA Preferred Stock dividend													(1,658,175)	(1,658,175)
Stock issued with debt									$ 3,996		642,722			646,718
Stock issued with debt, shares									399,650
Issuance of common stock warrants for interest paid-in-kind										600,298				600,298
Warrants issued with debt										1,403,546				1,403,546
Warrants issued for debt settlement										107,275				107,275
Net loss													(20,153,486)	(20,153,486)
Ending balance, value at Dec. 31, 2021	$ 3	$ 806	$ 100		$ 35	$ 68	$ 87		$ 91,206	$ 31,715,154	$ 64,261,048		$ (118,277,468)	$ (22,208,961)
Balance, shares at Dec. 31, 2021	300	80,570		21	3,458	6,880	8,649		9,120,526

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (20,153,486)	$ (16,005,543)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	65,194	76,586
Gain on loan forgiveness	(734,077)
Common stock and warrants issued for interest and extension fees	7,265,954	255,259
Depreciation and amortization	110,128	127,301
Accretion of discount on loan receivable		(6,250)
Accretion of interest and amortization of debt discount	6,738,802	5,436,863
Loss (Gain) on investment in equity securities	457,025	(500,358)
Loss on extinguishment of accrued liabilities and debt	130,279	1,036,638
Stock-based compensation expense	254,615	488,792
Common stock issued for services	794,562	179,077
Changes in operating assets and liabilities:
Accounts receivable	(23,518)	98,174
Inventories	(554,787)	24,949
Prepaid expenses and other assets	(107,681)	(101,387)
Accounts payable	(226,771)	(43,819)
Accrued employee compensation	15,106	(33,622)
Operating lease liability	(65,194)	(76,586)
Deferred revenue and other accrued expenses	1,165,276	4,160,732
Net cash used in operating activities	(4,868,573)	(4,883,194)
CASH FLOWS FROM INVESTING ACTIVITIES:
Advance on loan receivable		(795,000)
Purchases of property plant and equipment	(122,945)	(1,663)
Net cash used in investing activities	(122,945)	(796,663)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from related party debt	254,600	283,700
Payment on related party debt	(354,600)	(199,200)
Net proceeds from convertible debt	5,514,250	8,296,800
Payments on convertible debt	(1,833,295)	(2,857,007)
Net proceeds from non-convertible debt	2,010,688	1,290,539
Payments on non-convertible debt	(1,516,127)	(1,296,060)
Net proceeds from stock option exercises	14,773
Net proceeds from the issuance of Series AA Convertible Preferred Stock	1,015,000	150,000
Net cash provided by financing activities	5,105,289	5,668,772
NET (DECREASE) IN CASH AND CASH EQUIVALENTS	113,771	(11,085)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	18,540	29,625
CASH AND CASH EQUIVALENTS AT END OF YEAR	132,311	18,540
SUPPLEMENTAL INFORMATION
Interest paid in cash	921,569	764,600
NON CASH TRANSACTIONS:
Conversion of debt for Series AA preferred stock	500,250	110,000
Discount due to beneficial conversion feature	1,320,331	1,756,311
Discount from warrants issued with debt	1,403,546	4,863,959
Common stock issued in lieu of cash for dividend	184,274	299,709
Common stock issued with debt	646,718	214,419
Common stock issued to settle accrued liabilities		127,855
Common stock issued for debt settlement		374,550
Common stock issued for cashless warrants exercise	363
Conversion of debt and interest into common stock	2,989,990	2,220,442
Preferred stock dividend	1,658,175	1,517,987
Deemed dividend-beneficial conversion feature	873,798	61,180
Loan extension fees and interest added to principal		152,552
Recognition of right of use asset and liability	$ 239,327	$ 221,432

Business Overview

Business Overview	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	(1) Business Overview Pressure Biosciences, Inc. (“we”, “our”, “the Company”) develops and sells innovative, broadly enabling, high pressure-based platform technologies and related consumables for the worldwide life sciences, agriculture, food and beverage, and other key industries. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Historically, our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. In more recent years, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. On February 8, 2021, PBI announced plans to acquire the assets of a global eco-friendly agrochemical supplier. On April 14, 2021, PBI finalized terms and executed a new letter of intent to purchase the assets of the agrochemical supplier. This opportunity is attractive as it has the potential of readily producing significant revenue, as well as the potential to apply the UST technology to improve some of the product line. In July 2021, a newly-formed subsidiary of PBI, PBI Agrochem, leased a warehouse in Carson City, NV, and hired a warehouse manager.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	(2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations since our inception. As of December 31, 2021, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Notes 9 and 10 and have completed debt financing subsequent to December 31, 2021. We have financing efforts in place to continue to raise cash through debt and equity offerings. Management has developed a plan to continue operations. This plan includes obtaining equity or debt financing. During the year ended December 31, 2021 we received $ 7,779,538 net proceeds in additional convertible and non-convertible debt. We also received $ 1,015,000 in net proceeds from the sale of Series AA Preferred Stock during the year. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. Management’s plans to alleviate these conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern include pursuing one or more of the following options to raise additional funding, none of which can be guaranteed or are entirely within the Company’s control: ● Raise funding through the possible additional sales of the Company’s common stock, including public or private equity financings. ● Raise additional loan funding. ● Continue to seek commercial partners to accelerate revenue growth from the PCT, BaroFold, and UST technology platforms. ● Earn payments pursuant to potential collaboration and license agreements for BaroFold patents. ● Seek strategic direct equity investments from existing and new commercial partners There can be no assurance, however, that the Company will receive cash proceeds from any of these potential resources or, to the extent cash proceeds are received, those proceeds would be sufficient to support the Company’s operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. Generally, management’s plans must be approved before the date the financial statements are issued to be considered probable of being effectively implemented. The future receipt of potential funding from the Company’s collaborators and other resources is not considered probable at this time because none of the Company’s current plans have been finalized at the time of filing this Annual Report on Form 10-K. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The Company believes that its $ 132,311 If the Company is unable to raise capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, the Company would be forced to delay, reduce or eliminate its research and development programs and any future commercialization efforts. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation. ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. iii Recent Accounting Pronouncement In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. The standard is effective for the Company for interim and annual periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, Debt with Conversion and Other Options and Derivatives and Hedging - Contracts in Entity’s Own Equity. The standard is effective for interim and annual periods beginning after December 15, 2023 for the Company. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. iv. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2021 2020 North America 1,179 844 Europe 289 88 Asia 534 289 2,002 1,221 Year Ended December 31, Major products/services lines 2021 2020 Hardware 1,104 568 Consumables 274 205 Contract research services 268 193 Agrochem Products 29 - Sample preparation accessories 140 116 Technical support/extended service contracts 119 96 Shipping and handling 51 29 Other 17 14 2,002 1,221 Year Ended December 31, Timing of revenue recognition 2021 2020 Transferred at a point in time 1,674 978 Transferred over time 328 243 2,002 1,221 Contract balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2021 December 31, 2020 Receivables, which are included in ‘Accounts Receivable’ 155 131 Contract liabilities (deferred revenue) 41 67 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service 37 4 41 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. v. Beneficial Conversion Features In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options” the Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security. vi. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents. vii. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life. viii. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2021 2020 Raw materials $ 296,892 $ 217,682 Finished goods 1,193,158 717,581 Inventory reserve (342,496 ) (342,496 ) Total $ 1,147,554 $ 592,767 ix. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets. x. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2021, and 2020, the outstanding balance for intangible assets was $ 403,846 490,385 xi. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment xii. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2021, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2021 2020 Top Five Customers 44 % 33 % Federal Agencies 6 % 4 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2021 2020 Top Five Customers 82 % 89 % Federal Agencies 5 % 10 % Investment in Equity Securities As of December 31, 2021, we held 100,250 We had exchanged 33,334 shares of our common stock for the 100,250 shares we had held in Everest (before the Nexity Merger). We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of December 31, 2021, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 59,976 457,025 xiii. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: Schedule of Computation of Loss Per Share 2021 2020 Numerator: Net loss attributable to common shareholders $ (22,685,459 ) $ (17,584,710 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 6,636,523 3,304,187 Loss per common share - basic and diluted $ (3.42 ) $ (5.32 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Stock options 1,333,101 1,355,901 Convertible debt 5,232,118 4,474,868 Common stock warrants 16,207,108 14,434,702 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 26,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 115,267 Series K Convertible Preferred 229,334 229,334 Series AA Convertible Preferred 8,649,000 8,043,000 31,921,119 28,808,263 xiv. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2021 and 2020, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2021 and 2020. xv. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee and non employee awards are accounted for under ASC 718 where the awards are valued at grant date. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation 5 The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2021: Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 % We recognized stock-based compensation expense of $ 254,615 488,792 Schedule of Stock Based Compensation Expense 2021 2020 Research and development $ 128,094 $ 141,202 Selling and marketing 22,233 34,142 General and administrative 104,288 313,448 Total stock-based compensation expense $ 254,615 $ 488,792 During the years ended December 31, 2021 and 2020, the total fair value of stock options awarded was $ 49,135 0 As of December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $ 140,455 , which is expected to be recognized over weighted average period of 1.09 years. xvi. Advertising Advertising costs are expensed as incurred. We incurred $ 17,594 19,572 xvii. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates. xviii. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1. The Company does not have any financial liabilities that are required to be measured on a recurring basis at December 31, 2021 and 2020. The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2021: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 59,976 $ 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ $ The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2020: Fair value measurements at December 31, 2020 using: December 31, 2020 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 517,001 517,001 - - Total Financial Assets $ 517,001 $ 517,001 $ $

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment as of December 31, 2021 and 2020 consisted of the following components: Schedule of Property and Equipment 2021 2020 December 31, 2021 2020 Laboratory and manufacturing equipment $ 353,379 $ 240,670 Office equipment 194,999 184,763 Leasehold improvements 25,248 25,248 PCT collaboration, demonstration and leased systems 53,098 53,098 Total property and equipment 626,724 503,779 Less accumulated depreciation (510,878 ) (487,289 ) Net book value $ 115,846 $ 16,490 Depreciation expense for the years ended December 31, 2021 and 2020 was $ 23,589 40,763

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(5) Intangible Assets Intangible assets as of December 31, 2021 reflect the purchase price attributable to patents received in connection with the acquisition of assets of BaroFold Corp. Acquired BaroFold patents are being amortized to expense on a straight line basis at the rate of $ 80,000 9 80,000 Schedule of Intangible Assets 2021 2020 December 31, 2021 2020 BaroFold Patents $ 750,000 $ 750,000 Less accumulated amortization (346,154 ) (259,615 ) Net book value $ 403,846 $ 490,385 Amortization expense for each of the years ended December 31, 2021 and 2020 was $ 86,539 and $ 86,538 , respectively.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Retirement Plan	(6) Retirement Plan We provide all of our employees with the opportunity to participate in our retirement savings plan. Our retirement savings plan has been qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the plan through payroll deductions within statutory limitations and subject to any limitations included in the plan. During 2021 and 2020 we contributed $ 11,752 and $ 13,436 , respectively, in the form of discretionary Company-matching contributions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	(7) Income Taxes Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2021 and 2020, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2021 and 2020. Our tax returns for fiscal years 2018, 2019 and 2020 are open to examination. Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Deferred Tax Liabilities 2021 2020 Long term deferred taxes: Inventories $ 93,570 $ 93,570 Accrued expenses 91,792 156,699 Other 15,169 15,169 Non-cash, stock-based compensation, nonqualified 814,202 1,206,664 Impairment loss on investment 104,609 104,609 Operating loss carry forwards and tax credits 28,435,535 22,062,690 Less: valuation allowance (29,554,877 ) (23,639,401 ) Total net deferred tax assets $ - $ - A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, we established a valuation allowance in 2021 and 2020 for the full amount of our deferred tax assets for the uncertainty of realization. We believe that based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2021. We have net operating loss carry-forwards for federal income tax purposes of approximately $ 98,933,918 as of December 31, 2021. Included in these numbers are loss carry-forwards that were obtained through the acquisition of BioSeq, Inc. and are subject to Section 382 NOL limitations. These net operating loss carry-forwards expire at various dates from 2022 through 2037 . Under the Tax Reform Act, NOL’s generated after December 31, 2017 can offset only 80% of a corporation’s taxable income in any year. With limited exceptions, NOL’s generated after 2017, $ 57,298,328 cannot be carried back, but they can be carried forward indefinitely. We have net operating loss carry-forwards for state income tax purposes of approximately $ 94,663,553 at December 31, 2021. These net operating loss carry-forwards expire at various dates from 2031 through 2038 . We have research and development tax credit carry-forwards for federal income tax purposes of approximately $ 1,288,308 as of December 31, 2021 and research and development tax credit carry-forwards for state income tax purposes of approximately $ 306,425 as of December 31, 2021. The federal credit carry-forwards expire at various dates from 2022 through 2037. The state credit carry-forwards expire at various dates from 2023 through 2034 . The following table reconciles the U.S. Federal statutory tax rate to the Company’s effective tax rate: Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate 2021 2020 Statutory U.S. Federal tax rate 21 % 21 % Permanent differences ( 0 )% ( 0 )% State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Valuation allowance ( 21 )% ( 21 )% Effective tax rate - % - %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $ 6,950 December 31, 2022 We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023 7,282 The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $ 221,432 12 On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term. The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $ 239,327 based on the net present value of lease payments discounted using an estimated borrowing rate of 12 %. Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2021: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 230,318 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 562,757 Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle 1,200 2,000 3,000 4,000 5,000 Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $ 1,400 for the use of a lab bench, shared space and other utilities, and $ 2,000 per day for technical support services as needed. The agreement requires TDI to pay the Company a minimum royalty fee of $ 60,000 in 2020 and $ 60,000 in 2021. For the years ended December 31, 2020 and 2021, we reported expenses of $ 82,800 86,800 Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the control change.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	(9) Convertible Debt and Other Debt Convertible Debt On various dates during the year ended December 31, 2020, the Company issued convertible notes for net proceeds of approximately $ 8.3 million which contained varied terms and conditions as follows: a) 6 - 12 month maturity date; b) interest rates of 10 - 18 % per annum c) convertible to the Company’s common stock at issuance at a fixed rate of $ 2.50 . These notes were issued with shares of common stock or warrants to purchase common stock that were fairly valued at issuance dates. The aggregate relative fair value of the shares of common stock issued with the notes of $ 214,419 was recorded as a debt discount to be amortized over the term of the notes. The aggregate relative fair value of the warrants issued with the notes of $ 4.9 million was also recorded as a debt discount to be amortized over the term of the notes. We then computed the effective conversion price of the notes and recorded a BCF of $ 1.8 million as a debt discount to be amortized over the term of the notes. Finally, we evaluated our convertible notes for derivative liability treatment on an on-going basis and have determined that all our notes did not qualify for derivative accounting treatment at December 31, 2020. In the year ended December 31, 2020 the amortization of debt discount on convertible notes was $ 5,118,222 . On various dates during the year ended December 31, 2021, the Company issued convertible notes for net proceeds of approximately $ 5.5 million which contained varied terms and conditions as follows: a) 6 - 12 month maturity date; b) interest rates of 10 - 18 % per annum and c) convertible to the Company’s common stock at issuance at fixed rates of $ 2.50 and $ 3.00 or at a variable conversion rates upon the Company’s up-listing to NASDAQ or NYSE or an event of default. These notes were issued with shares of common stock or warrants to purchase common stock that were fair valued at issuance dates. The aggregate relative fair value of the shares of common stock issued with the notes of $ 646,718 was recorded as a debt discount to be amortized over the term of the notes. The aggregate relative fair value of $ 1.4 million for the warrants issued with the notes was recorded as a debt discount to be amortized over the term of the notes. We then computed the effective conversion price of the notes and recorded a BCF of $ 1.3 million as a debt discount to be amortized over the term of the notes. Finally, we evaluated our convertible notes for derivative liability treatment on an on-going basis and have determined that all our notes did not qualify for derivative accounting treatment at December 31, 2021. In the year ended December 31, 2021 the amortization of debt discount on convertible notes was approximately $ 6.7 million. The specific terms of the convertible notes and outstanding balances as of December 31, 2021 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 12 months $ 380,000 $ 166,703 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 $ - June 4, 2019 9 months $ 500,000 $ 302,484 $ - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 12 months $ 115,000 $ 115,000 $ - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ - November 15, 2019 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24, 2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17, 2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 $ - $ 96,208 April 30, 2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18, 2020 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12, 2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 September 25, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ - $ 19,125 December 3, 2020 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 (1) (5) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 $ - $ 36,431 May 24, 2021 6 months $ 54,625 $ 4,625 $ 7,125 12 % $ 2.50 $ - $ - May 6, 2021 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 $ - $ 773,802 May 20, 2021 12 months $ 180,000 $ 30,000 $ 30,000 10 % $ 2.50 $ 15,000 $ 25,824 June 3, 2021 6 months $ 50,000 $ 50,000 $ 1,500 12 % $ 2.50 $ - $ 7,948 June 28, 2021 12 months $ 350,000 $ 350,000 $ 35,000 12 % (6 ) $ 22,750 $ 267,250 July 3, 2021 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 July 1, 2021 6 months $ 260,000 $ 260,000 $ 10,000 12 % $ 2.50 $ - $ 89,640 July 6, 2021 6 months $ 125,000 $ 125,000 $ - 12 % $ 2.50 $ - $ 42,031 July 6, 2021 6 months $ 125,000 $ 125,000 $ - 12 % $ 2.50 $ - $ 42,031 July 15, 2021 6 months $ 100,000 $ 100,000 $ 5,000 12 % (7 ) $ - $ 57,716 July 16, 2021 6 months $ 50,000 $ 50,000 $ 2,000 12 % $ 3.00 $ - $ 40,806 July 16, 2021 6 months $ 306,250 $ 306,250 $ 56,250 (3 ) (8 ) $ 22,500 $ 227,500 July 16, 2021 6 months $ 306,250 $ 306,250 $ 56,250 (3 ) (8 ) $ 12,500 $ 237,500 July 16, 2021 6 months $ 122,500 $ 122,500 $ 22,500 (3 ) (8 ) $ 5,000 $ 95,000 August 31, 2021 6 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 Sept. 8, 2021 8 months $ 78,000 $ 78,000 $ 3,000 12 % (7 ) $ - $ 40,449 Sept. 10, 2021 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) $ - $ 43,520 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % $ (7 ) $ - $ 108,801 Sept. 16, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % $ (7 ) $ - $ 112,337 Sept. 24, 2021 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) $ - $ 61,876 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 $ - October 21, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ - $ 96,991 December 7, 2021 12 months $ 169,500 $ 169,500 $ 19,500 12 % $ (10 ) $ 3,750 $ - $ 14,376,462 $ 1,661,225 $ 1,039,250 $ 9,508,836 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lender have agreed to the extension of the Standstill and Forbearance agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and Interest rate is. 18.4 (4) During the year ended December 31, 2020 the Company entered into Rate Modification Agreements with these lenders. In these agreements five lenders agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $ 2.50 90 (7) Notes can be voluntary converted before maturity at $ 2.50 per share or mandatorily converted on up-list at lower of $ 2.50 or up-list price. (8) Notes can be converted at the lesser of $ 2.50 25 (9) Conversion price of this note is $ 2.50 (10) Loan is convertible, upon an event of default, at the lowest closing bid price for the Company’s common stock for the five As of December 31, 2021 one lender holds approximately $ 9.4 million of the $ 14.4 million convertible notes outstanding. For the year ended December 31, 2021, the Company recognized amortization expense related to the debt discounts indicated above of $ 6,689,238 . The unamortized debt discounts as of December 31, 2021 related to the convertible debentures amounted to $ 1,536,649 . For the year ended December 31, 2020, the Company recognized amortization expense related to the debt discounts indicated above $ 5,118,222 . The unamortized debt discounts as of December 31, 2020 related to the convertible debentures and other convertible notes amounted to $ 3,948,167 . Standstill and Forbearance Agreements The Company has entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes with a total principal as of June 30, 2021 of $ 1.57 469,000 1.1 827,500 741,500 $1.47 million in connection with Standstill and Forbearance agreements. (See Note 11) Convertible Loan Modifications and Extinguishments According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications The cash flows of new debt exceeded 10 % of the remaining cash flows of the original debt on several loans in 2021 and 2020. We recorded losses on extinguishment of liabilities of $ 1,795,150 in 2021 and $ 3,575,878 in 2020. Our gains and losses were measured by calculating the difference of the fair value of the new debt and the carrying value of the old debt. The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2021: Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts 2021 Balance at January 1, $ 7,545,670 Issuance of convertible debt, face value 6,406,375 Deferred financing cost (892,125 ) Beneficial conversion feature on convertible note (1,320,331 ) Debt discount from shares and warrants issued with debt (2,050,264 ) Conversion of debt into equity (1,705,455 ) Payments (1,833,295 ) Accretion of interest and amortization of debt discount to interest expense through December 31 6,689,238 Balance at December 31 12,839,813 Less: current portion 12,839,813 Convertible debt, long-term portion $ - Other Notes On September 9, 2019 and February 28, 2020 we received a total of $ 966,500 unsecured non-convertible loans from a private investor with a one-month term. During the year ended December 31, 2020, the Company received net proceeds of $ 463,500 , issued 150,000 warrants to purchase common stock ( five -year term and $ 3.50 exercise price) and repaid $ 275,000 . The relative fair value of $ 185,660 of the warrants issued with the note was recorded as a debt discount to be amortized over the term of the notes. As of December 31, 2021 and 2020 the Company owes $ 691,500 and $ 691,500 , respectively on these notes which are past due. The Company and the investor are negotiating in good faith to extend the loans. On October 1, 2019, the Company and the holder of the $ 170,000 1,200 10 On October 11, 2019 we received a non-convertible loan with a one month term and a 2 % interest charge for $ 25,000 from a private investor. In the year ended December 31,2021 the Company issued 17 17,000 five year 3.50 Merchant Agreements During the years ended December 31, 2021 and 2020 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 9.3 % - 14% . As illustrated in the following table, under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the disclosed Daily Payment Rate. The Company’s Chief Executive The following table shows our Merchant Agreements as of December 31, 2021: Schedule of Merchant Agreements Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly 11,305.00 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily 1,279.00 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500 The following table shows our Merchant Agreements as of December 31, 2020: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees November 5, 2020 $ 200,000 $ 275,800 $ 163,955 Daily 1,724.00 $ - November 19, 2020 100,000 137,900 85,013 Daily 985.00 $ 300,000 $ 413,700 $ 248,968 $ - We have accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. We amortized $ 49,564 and $ 318,641 of debt discounts during the years ended December 31, 2021 and 2020, respectively for all non-convertible notes. The total unamortized discount for all non-convertible notes as of December 31, 2021 and 2020 was $ 0 and $ 0 , respectively. Related Party Notes During the year ended December 31, 2021, we received short-term non-convertible loans of $ 254,600 from related parties and repaid $ 354,600 of related party loans. These notes bear interest ranging from 0 % to 15 % interest and are due upon demand. In this period we also issued 69.5 69,450 five 3.50 66,000 107,625 Long term debt During the year ended December 31, 2020, the Company borrowed $ 527,039 through COVID-19 programs that were sponsored by the United States and administered by the Small Business Administration (the “SBA”). The most notable programs were the Payroll Protection Program (or “2020 PPP”) and the Economic Injury Disaster Loan program (or “EIDL”). Under the 2020 PPP, the Company borrowed $ 367,039 ( two -year term and 1% interest rate per annum). 150,000 , accrues interest at 3.75 % and requires monthly payments of $ 731 for principal and interest beginning in June 2021. The balance of the principal will be due in 30 years . In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the year ended December 31, 2021, the Company borrowed $ 367,039

Stockholders_ (Deficit)

Stockholders’ (Deficit)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ (Deficit)	(10) Stockholders’ (Deficit) Preferred Stock We are authorized to issue 1,000,000 0.01 1,000,000 1) 20,000 Junior A 2) 313,960 Series A 3) 279,256 Series B 4) 88,098 Series C 5) 850 Series D 6) 500 (“Series E”) 7) 240,000 Series G 8) 10,000 Series H 9) 21 Series H2 10) 6,250 Series J 11) 15,000 Series K 12) 10,000 Series AA As of December 31, 2021, there were no shares of Junior A issued and outstanding, and no shares of Series A, B, C, and E issued and outstanding. Series D Convertible Preferred Stock On November 11, 2011, we completed a registered direct offering, pursuant to which we sold an aggregate of 843 units for a purchase price of $ 1,000 per unit, resulting in gross proceeds to us of $ 843,000 (the “ Series D Placement Series D Unit 0.01 par value per share (the “ Series D Convertible Preferred Stock 84 shares of our common stock, (subject to adjustment for stock splits, stock dividends, recapitalization, etc.) and (ii) one five -year warrant to purchase approximately 21 shares of our common stock at a per share exercise price of $ 24.30 , subject to adjustment as provided in the Warrants (“ Series D Warrant The Series D Convertible Preferred Stock will rank senior to the Company’s common stock with respect to payments made upon liquidation, winding up or dissolution. Upon any liquidation, dissolution or winding up of the Company, after payment of the Company’s debts and liabilities, and before any payment is made to the holders of any junior securities, the holders of Series D Convertible Preferred Stock will first be entitled to be paid $ 1,000 We may not pay any dividends on shares of common stock unless we also pay dividends on the Series D Convertible Preferred Stock in the same form and amount, on an as-if-converted basis, as dividends actually paid on shares of our common stock. Except for such dividends, no other dividends may be paid on the Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock is convertible into 84 19.50 Series D Conversion Ratio 300 50,000 In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50 The holders of Series D Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except that the holders of Series D Convertible Preferred Stock may vote separately as a class on any matters that would (i) amend, our Restated Articles of Organization, as amended, in a manner that adversely affects the rights of the Series D Convertible Preferred Stock, (ii) alter or change adversely the powers, preferences or rights of the Series D Convertible Preferred Stock or alter or amend the certificate of designation, (iii) authorize or create any class of shares ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series D Convertible Preferred Stock, or (iv) increase the number of authorized shares of Series D Convertible Preferred Stock. If, within 12 months of the initial issuance of the Series D Convertible Preferred Stock, we issue any common stock, common stock equivalents, indebtedness or any combination thereof (a “ Subsequent Financing the holders of Series D Convertible Preferred Stock will have the right to participate on a pro-rata basis in up to 50% of such Subsequent Financing Series D Warrants On May 10, 2017, we received net proceeds of $ 140,214 from the exercise of 19,889 stock purchase warrants from the Series D registered direct offering on November 10, 2011. In consideration for the warrant exercises, we issued to the investors warrants to purchase 39,778 shares of our Common Stock at an exercise price per share equal to $ 8.40 per share. The warrants expired on the third year anniversary date. We determined the fair value of $ 186,802 for these warrants and recorded the value as other expenses. All of these warrants have expired. Series G Convertible Preferred Stock On July 6 and November 15, 2012, we completed a private placement, pursuant to which we sold an aggregate of 4,844 units for a purchase price of $ 150.00 per unit (the “Series G Purchase Price”), resulting in gross proceeds to us of $ 726,600 (the “ Series G Private Placement Series G Unit 0.01 par value per share (the “Series G Preferred Stock”) convertible into 1 share of our common stock, (subject to adjustment for stock splits, stock dividends, recapitalization, etc.) and (ii) a three -year warrant to purchase 1 share of our common stock at a per share exercise price of $ 15.00 (the “ Series G Warrant Each share of Series G Preferred Stock will receive a cumulative dividend at the annual rate of (i) four percent ( 4 100,000 6 100,000 250,000 12 250,000 At the election of the Company and upon required advanced notice, each share of Series G Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) if, after 6 months from the original issuance date of the Series G Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price equal to at least $ 22.50 334 22.50 2.5 The holders of Series G Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series H Convertible Preferred Stock On December 28, 2012 the Company amended the Articles of Incorporation to authorize 10,000 33,334 10,000 0.01 Series H Preferred Stock 24.08 4 24.08 Series H2 Convertible Preferred Stock On December 23, 2014 the Company amended the Articles of Incorporation to authorize 21 70,000 0.01 21 0.01 Series H2 Preferred Stock 7.50 3,334 7.50 Series J Convertible Preferred Stock On February 6, March 28 and May 20, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 5,087.5 units for a purchase price of $ 400.00 per unit (the “Purchase Price”), or an aggregate Purchase Price of $ 2,034,700 . Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series J Convertible Preferred Stock, par value $ 0.01 per share (the “Series J Convertible Preferred Stock”), convertible into 34 shares of the Company’s common stock, par value $ 0.01 per share and (ii) a warrant to purchase 34 shares of common stock at an exercise price equal to $ 12.00 per share. The warrants expired three years from the issuance date. From the date of issuance of any shares of Series J Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series J Convertible Preferred Stock, dividends will accrue on each share of Series J Convertible Preferred Stock at an annual rate of (i) four percent ( 4 250,000 6 250,000 Each share of Series J Convertible Preferred Stock is convertible into 34 At the election of the Company and upon required advance notice, each share of Series J Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series J Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $ 24.00 1,667 24.00 2.5 The holders of Series J Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series K Convertible Preferred Stock From the date of issuance of any shares of Series K Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series K Convertible Preferred Stock, dividends will accrue on each share of Series K Convertible Preferred Stock at an annual rate of (i) four percent ( 4 100,000 6 $100,000 Each share of Series K Convertible Preferred Stock is convertible into 34 At the election of the Company and upon required advance notice, each share of Series K Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series K Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $ 24.00 1,667 24.00 2.5 The holders of Series K Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series AA Convertible Preferred Stock and Warrants During the year ended December 31, 2020, the Company entered into Securities Purchase Agreements with accredited investors pursuant to which the Company sold an aggregate of 60 1,000 0.01 150,000 60,000 3.50 110,000 44 44,000 five 3.50 38,783 During the year ended December 31, 2021, the Company entered into Securities Purchase Agreements with accredited investors pursuant to which the Company sold an aggregate of 406 shares of Series AA Convertible Preferred Stock, each preferred share convertible into 1,000 shares of the Company’s common stock, par value $ 0.01 per share, for an aggregate Purchase price of approximately $ 1,015,000 . We issued to the investors warrants to purchase an aggregate 406,000 shares of common stock with an exercise price of $ 3.50 per share. The Company did not incur any placement agent fees for this transaction. The relative fair value of warrants is $ 509,130 . In this time the Company also issued 200 200,100 five year 3.50 245,635 23,004 The issuances of our convertible preferred stock and common stock purchase warrants are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a derivative, then it is measured at fair value using the Black Scholes Option Model and recorded as a liability on the balance sheet. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”). If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible preferred stock. We analyzed these warrants issued in 2021 and determined that they were not considered derivatives and therefore recorded the aggregate relative fair value of $ 509,130 406,000 We analyzed the warrants issued in 2020 and determined that they were not considered derivatives and therefore recorded the aggregate relative fair value of $ 69,580 60,000 The convertible preferred stock is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible preferred stock is examined for any intrinsic BCF of which the convertible price of the preferred stock is less than the closing stock price on date of issuance. If the relative fair value method is used to value the convertible preferred stock and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares of common stock the convertible preferred stock is converted into by its terms. The adjusted BCF value of $ 873,798 61,180 Common Stock Stock Options and Warrants At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Consistent with the Company’s existing 2013 Equity Incentive plan (the “2013 plan”), under the 2021 plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of December 31, 2021, options to acquire 1,333,101 shares were outstanding under these Plans. All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance. As of December 31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $ 304,900 , which is expected to be recognized over weighted average period of 1.59 years. The aggregate intrinsic value associated with the options outstanding and exercisable and the aggregate intrinsic value associated with the warrants outstanding and exercisable as of December 31, 2020, based on the December 31, 2020 closing stock price of $ 2.12 , was $ 1,240,469 . At this time the warrants had a weighted average remaining contractual term of 3.10 zero 24,000 49,135 2.17 three ten As of December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $ 140,455 , which is expected to be recognized over weighted average period of 1.09 years. The aggregate intrinsic value associated with the options outstanding and exercisable and the aggregate intrinsic value associated with the warrants outstanding and exercisable as of December 31, 2021, based on the December 31, 2021 closing stock price of $ 2.31 , was $ 2,124,104 . At this time the warrants had a weighted average remaining contractual term of 2.39 zero The following tables summarize information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Total Shares Weighted Shares Weighted Shares Exercisable Balance outstanding, January 1, 2020 1,396,302 $ 0.69 9,893,034 $ 3.52 11,289,336 10,148,543 Granted - - 4,925,031 3.50 4,925,031 Exercised - - - - - Expired - - (383,363 ) 4.01 (383,363 ) Forfeited (40,401 ) 0.78 - - (40,401 ) Balance outstanding, December 31, 2020 1,355,901 $ 0.71 14,434,702 $ 3.50 15,790,603 15,302,830 Granted 24,000 2.17 2,235,408 3.57 2,259,408 Exercised (21,411 ) 0.69 (187,500 ) 3.50 (208,911 ) Expired - - (275,502 ) 3.50 (275,502 ) Forfeited (25,389 ) 0.69 - - (25,389 ) Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Number of Remaining Exercise Number of Remaining Exercise $ 0.69 $ 1.00 1,309,101 7.7 $ 0.69 1,101,459 7.6 $ 0.69 $ 1.01 $ 3.00 24,000 9.1 $ 2.17 - - $ - 1,333,101 7.8 $ 0.72 1,101,459 7.6 $ 0.69 Common Stock Issuances On various dates in the year ended December 31, 2021 the Company issued 333,200 shares with a fair value of $794,562 for services rendered; 36,290 shares for a cashless warrant exercise; 82,373 $184,274 in lieu of cash for the 8% dividend on Series AA Convertible Preferred Stock; 1,195,996 shares with a fair value of $2,989,990 for the conversion of debt and interest for common stock; 2,883,282 shares with a fair value of $6,665,656 for debt extension, settlement and interest payments, 21,411 shares for stock option exercises (at an exercise price of $ 0.69 399,650 shares with a fair value of $646,718 in conjunction with the signing of new convertible loans. During this period, we also issued 1,146,945 three five 3.50 5.00 1.4 71,042 3 3.5 107,275 As profiled in the following table, for seven loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Percentage of Loan Defined Shares Issuable Loan Loan Issuance Date Principal Principal Issuable Date Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 September 23, 2020 $ 15,000 0.0652 % December 1, 2020 Weekly Loan 4 September 25, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 5 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 6 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly Loan 7 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly During the year ended December 31, 2021, the Company accrued $ 6,288,529 For our loan dated December 23, 2020, we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 3.50 600,298 10,000 On various dates in the year ended December 31, 2020 the Company issued a total of 1,618,704 shares of restricted common stock at a fair value of approximately $ 3,671,311 to accredited investors. 76,800 179,077 122,135 299,709 8 871,309 shares with a fair value of $ 2,220,442 were issued for the conversion of debt and interest for common stock; 323,260 of the shares with a fair value of $ 629,809 were issued for debt extension, settlement and interest payments, 66,500 127,855 were issued to settle an accrued liability and 158,700 of the shares with a fair value of $ 214,419 were issued in conjunction with the signing of new convertible loans.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	(11) Subsequent Events From January 1, 2022 through March 31, 2022 the Company received two convertible loans for $ 145,487 12 One loan is convertible at $ 2.50 177,500 from related parties with 10% 12% Merchant Cash lender agreements (collecting $ 361,120 18,990 In this time the Company also rolled over two loans totaling $ 475,000 1,200,000 six eight months 132,000 1,045,000 five six months 1,095,250 147,500 During this period the Company also issued 140,200 350,500 134,805 37,000 30,000 three year 3.50 107,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiaries PBI BioSeq, Inc and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Recent Accounting Pronouncement	iii Recent Accounting Pronouncement In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. The standard is effective for the Company for interim and annual periods beginning after December 15, 2022. The Company is evaluating the impact of this standard on its Consolidated Financial Statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, Debt with Conversion and Other Options and Derivatives and Hedging - Contracts in Entity’s Own Equity. The standard is effective for interim and annual periods beginning after December 15, 2023 for the Company. The Company is evaluating the impact of this standard on its Consolidated Financial Statements.
Revenue Recognition	iv. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2021 2020 North America 1,179 844 Europe 289 88 Asia 534 289 2,002 1,221 Year Ended December 31, Major products/services lines 2021 2020 Hardware 1,104 568 Consumables 274 205 Contract research services 268 193 Agrochem Products 29 - Sample preparation accessories 140 116 Technical support/extended service contracts 119 96 Shipping and handling 51 29 Other 17 14 2,002 1,221 Year Ended December 31, Timing of revenue recognition 2021 2020 Transferred at a point in time 1,674 978 Transferred over time 328 243 2,002 1,221 Contract balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2021 December 31, 2020 Receivables, which are included in ‘Accounts Receivable’ 155 131 Contract liabilities (deferred revenue) 41 67 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service 37 4 41 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Beneficial Conversion Features	v. Beneficial Conversion Features In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options” the Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.
Cash and Cash Equivalents	vi. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents.
Research and Development	vii. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
Inventories	viii. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2021 2020 Raw materials $ 296,892 $ 217,682 Finished goods 1,193,158 717,581 Inventory reserve (342,496 ) (342,496 ) Total $ 1,147,554 $ 592,767
Property and Equipment	ix. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
Intangible Assets	x. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2021, and 2020, the outstanding balance for intangible assets was $ 403,846 490,385
Long-Lived Assets	xi. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment
Concentrations	xii. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2021, we determined that no allowance against accounts receivable was necessary. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2021 2020 Top Five Customers 44 % 33 % Federal Agencies 6 % 4 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2021 2020 Top Five Customers 82 % 89 % Federal Agencies 5 % 10 % Investment in Equity Securities As of December 31, 2021, we held 100,250 We had exchanged 33,334 shares of our common stock for the 100,250 shares we had held in Everest (before the Nexity Merger). We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of December 31, 2021, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs, of our investment in Nexity to be $ 59,976 457,025
Computation of Loss per Share	xiii. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: Schedule of Computation of Loss Per Share 2021 2020 Numerator: Net loss attributable to common shareholders $ (22,685,459 ) $ (17,584,710 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 6,636,523 3,304,187 Loss per common share - basic and diluted $ (3.42 ) $ (5.32 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Stock options 1,333,101 1,355,901 Convertible debt 5,232,118 4,474,868 Common stock warrants 16,207,108 14,434,702 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 26,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 115,267 Series K Convertible Preferred 229,334 229,334 Series AA Convertible Preferred 8,649,000 8,043,000 31,921,119 28,808,263
Accounting for Income Taxes	xiv. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2021 and 2020, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2021 and 2020.
Accounting for Stock-Based Compensation	xv. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee and non employee awards are accounted for under ASC 718 where the awards are valued at grant date. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation 5 The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2021: Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 % We recognized stock-based compensation expense of $ 254,615 488,792 Schedule of Stock Based Compensation Expense 2021 2020 Research and development $ 128,094 $ 141,202 Selling and marketing 22,233 34,142 General and administrative 104,288 313,448 Total stock-based compensation expense $ 254,615 $ 488,792 During the years ended December 31, 2021 and 2020, the total fair value of stock options awarded was $ 49,135 0 As of December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $ 140,455 , which is expected to be recognized over weighted average period of 1.09 years.
Advertising	xvi. Advertising Advertising costs are expensed as incurred. We incurred $ 17,594 19,572
Fair Value of Financial Instruments	xvii. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.
Fair Value Measurements	xviii. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1. The Company does not have any financial liabilities that are required to be measured on a recurring basis at December 31, 2021 and 2020. The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2021: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 59,976 $ 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ $ The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2020: Fair value measurements at December 31, 2020 using: December 31, 2020 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 517,001 517,001 - - Total Financial Assets $ 517,001 $ 517,001 $ $

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Year Ended December 31, Primary geographical markets 2021 2020 North America 1,179 844 Europe 289 88 Asia 534 289 2,002 1,221 Year Ended December 31, Major products/services lines 2021 2020 Hardware 1,104 568 Consumables 274 205 Contract research services 268 193 Agrochem Products 29 - Sample preparation accessories 140 116 Technical support/extended service contracts 119 96 Shipping and handling 51 29 Other 17 14 2,002 1,221 Year Ended December 31, Timing of revenue recognition 2021 2020 Transferred at a point in time 1,674 978 Transferred over time 328 243 2,002 1,221
Schedule of Contract Balances	Contract balances Schedule of Contract Balances In thousands of US dollars ($) December 31, 2021 December 31, 2020 Receivables, which are included in ‘Accounts Receivable’ 155 131 Contract liabilities (deferred revenue) 41 67
Schedule of Future Related to Performance Obligations	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service 37 4 41
Schedule of Inventories	Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: Schedule of Inventories 2021 2020 Raw materials $ 296,892 $ 217,682 Finished goods 1,193,158 717,581 Inventory reserve (342,496 ) (342,496 ) Total $ 1,147,554 $ 592,767
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: Schedule of Customer Concentration Risk Percentage 2021 2020 Top Five Customers 44 % 33 % Federal Agencies 6 % 4 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2021 2020 Top Five Customers 82 % 89 % Federal Agencies 5 % 10 %
Schedule of Computation of Loss Per Share	Schedule of Computation of Loss Per Share 2021 2020 Numerator: Net loss attributable to common shareholders $ (22,685,459 ) $ (17,584,710 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 6,636,523 3,304,187 Loss per common share - basic and diluted $ (3.42 ) $ (5.32 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Stock options 1,333,101 1,355,901 Convertible debt 5,232,118 4,474,868 Common stock warrants 16,207,108 14,434,702 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 26,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 115,267 Series K Convertible Preferred 229,334 229,334 Series AA Convertible Preferred 8,649,000 8,043,000 31,921,119 28,808,263
Summary of Assumptions for Grants of Stock Options	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2021: Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Expected life 6.0 (yrs) Expected volatility 155.02 % Risk-free interest rate 0.62 % Forfeiture rate 5.00 % Expected dividend yield 0.0 %
Schedule of Stock Based Compensation Expense	We recognized stock-based compensation expense of $ 254,615 488,792 Schedule of Stock Based Compensation Expense 2021 2020 Research and development $ 128,094 $ 141,202 Selling and marketing 22,233 34,142 General and administrative 104,288 313,448 Total stock-based compensation expense $ 254,615 $ 488,792
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2021: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 59,976 $ 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ $ The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2020: Fair value measurements at December 31, 2020 using: December 31, 2020 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 517,001 517,001 - - Total Financial Assets $ 517,001 $ 517,001 $ $

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of December 31, 2021 and 2020 consisted of the following components: Schedule of Property and Equipment 2021 2020 December 31, 2021 2020 Laboratory and manufacturing equipment $ 353,379 $ 240,670 Office equipment 194,999 184,763 Leasehold improvements 25,248 25,248 PCT collaboration, demonstration and leased systems 53,098 53,098 Total property and equipment 626,724 503,779 Less accumulated depreciation (510,878 ) (487,289 ) Net book value $ 115,846 $ 16,490

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Schedule of Intangible Assets 2021 2020 December 31, 2021 2020 BaroFold Patents $ 750,000 $ 750,000 Less accumulated amortization (346,154 ) (259,615 ) Net book value $ 403,846 $ 490,385

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Deferred Tax Liabilities	Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2021 and 2020 are as follows: Schedule of Deferred Tax Assets and Deferred Tax Liabilities 2021 2020 Long term deferred taxes: Inventories $ 93,570 $ 93,570 Accrued expenses 91,792 156,699 Other 15,169 15,169 Non-cash, stock-based compensation, nonqualified 814,202 1,206,664 Impairment loss on investment 104,609 104,609 Operating loss carry forwards and tax credits 28,435,535 22,062,690 Less: valuation allowance (29,554,877 ) (23,639,401 ) Total net deferred tax assets $ - $ -
Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate	The following table reconciles the U.S. Federal statutory tax rate to the Company’s effective tax rate: Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate 2021 2020 Statutory U.S. Federal tax rate 21 % 21 % Permanent differences ( 0 )% ( 0 )% State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Valuation allowance ( 21 )% ( 21 )% Effective tax rate - % - %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2021: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 230,318 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 562,757

Convertible Debt and Other De_2

Convertible Debt and Other Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible notes and outstanding balances as of December 31, 2021 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 12 months $ 380,000 $ 166,703 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 $ - June 4, 2019 9 months $ 500,000 $ 302,484 $ - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 12 months $ 115,000 $ 115,000 $ - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 12 months $ 78,750 $ 78,750 $ - 4 % $ 2.50 $ 3,750 $ - November 15, 2019 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24, 2020 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11, 2020 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17, 2020 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 $ - $ 96,208 April 30, 2020 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18, 2020 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12, 2020 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 September 25, 2020 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ - $ 19,125 December 3, 2020 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 (1) (5) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 $ - $ 36,431 May 24, 2021 6 months $ 54,625 $ 4,625 $ 7,125 12 % $ 2.50 $ - $ - May 6, 2021 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 $ - $ 773,802 May 20, 2021 12 months $ 180,000 $ 30,000 $ 30,000 10 % $ 2.50 $ 15,000 $ 25,824 June 3, 2021 6 months $ 50,000 $ 50,000 $ 1,500 12 % $ 2.50 $ - $ 7,948 June 28, 2021 12 months $ 350,000 $ 350,000 $ 35,000 12 % (6 ) $ 22,750 $ 267,250 July 3, 2021 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 July 1, 2021 6 months $ 260,000 $ 260,000 $ 10,000 12 % $ 2.50 $ - $ 89,640 July 6, 2021 6 months $ 125,000 $ 125,000 $ - 12 % $ 2.50 $ - $ 42,031 July 6, 2021 6 months $ 125,000 $ 125,000 $ - 12 % $ 2.50 $ - $ 42,031 July 15, 2021 6 months $ 100,000 $ 100,000 $ 5,000 12 % (7 ) $ - $ 57,716 July 16, 2021 6 months $ 50,000 $ 50,000 $ 2,000 12 % $ 3.00 $ - $ 40,806 July 16, 2021 6 months $ 306,250 $ 306,250 $ 56,250 (3 ) (8 ) $ 22,500 $ 227,500 July 16, 2021 6 months $ 306,250 $ 306,250 $ 56,250 (3 ) (8 ) $ 12,500 $ 237,500 July 16, 2021 6 months $ 122,500 $ 122,500 $ 22,500 (3 ) (8 ) $ 5,000 $ 95,000 August 31, 2021 6 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 Sept. 8, 2021 8 months $ 78,000 $ 78,000 $ 3,000 12 % (7 ) $ - $ 40,449 Sept. 10, 2021 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) $ - $ 43,520 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % $ (7 ) $ - $ 108,801 Sept. 16, 2021 6 months $ 250,000 $ 250,000 $ 12,500 12 % $ (7 ) $ - $ 112,337 Sept. 24, 2021 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) $ - $ 61,876 Sept. 15, 2021 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 $ - October 21, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ - $ 96,991 December 7, 2021 12 months $ 169,500 $ 169,500 $ 19,500 12 % $ (10 ) $ 3,750 $ - $ 14,376,462 $ 1,661,225 $ 1,039,250 $ 9,508,836 (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lender have agreed to the extension of the Standstill and Forbearance agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and Interest rate is. 18.4 (4) During the year ended December 31, 2020 the Company entered into Rate Modification Agreements with these lenders. In these agreements five lenders agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $ 2.50 90 (7) Notes can be voluntary converted before maturity at $ 2.50 per share or mandatorily converted on up-list at lower of $ 2.50 or up-list price. (8) Notes can be converted at the lesser of $ 2.50 25 (9) Conversion price of this note is $ 2.50 (10) Loan is convertible, upon an event of default, at the lowest closing bid price for the Company’s common stock for the five
Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts	The following table provides a summary of the changes in convertible debt, net of unamortized discounts, during 2021: Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts 2021 Balance at January 1, $ 7,545,670 Issuance of convertible debt, face value 6,406,375 Deferred financing cost (892,125 ) Beneficial conversion feature on convertible note (1,320,331 ) Debt discount from shares and warrants issued with debt (2,050,264 ) Conversion of debt into equity (1,705,455 ) Payments (1,833,295 ) Accretion of interest and amortization of debt discount to interest expense through December 31 6,689,238 Balance at December 31 12,839,813 Less: current portion 12,839,813 Convertible debt, long-term portion $ -
Schedule of Merchant Agreements	The following table shows our Merchant Agreements as of December 31, 2021: Schedule of Merchant Agreements Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly 11,305.00 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily 1,279.00 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500 The following table shows our Merchant Agreements as of December 31, 2020: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees November 5, 2020 $ 200,000 $ 275,800 $ 163,955 Daily 1,724.00 $ - November 19, 2020 100,000 137,900 85,013 Daily 985.00 $ 300,000 $ 413,700 $ 248,968 $ -

Stockholders_ (Deficit) (Tables

Stockholders’ (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Total Shares Weighted Shares Weighted Shares Exercisable Balance outstanding, January 1, 2020 1,396,302 $ 0.69 9,893,034 $ 3.52 11,289,336 10,148,543 Granted - - 4,925,031 3.50 4,925,031 Exercised - - - - - Expired - - (383,363 ) 4.01 (383,363 ) Forfeited (40,401 ) 0.78 - - (40,401 ) Balance outstanding, December 31, 2020 1,355,901 $ 0.71 14,434,702 $ 3.50 15,790,603 15,302,830 Granted 24,000 2.17 2,235,408 3.57 2,259,408 Exercised (21,411 ) 0.69 (187,500 ) 3.50 (208,911 ) Expired - - (275,502 ) 3.50 (275,502 ) Forfeited (25,389 ) 0.69 - - (25,389 ) Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Number of Remaining Exercise Number of Remaining Exercise $ 0.69 $ 1.00 1,309,101 7.7 $ 0.69 1,101,459 7.6 $ 0.69 $ 1.01 $ 3.00 24,000 9.1 $ 2.17 - - $ - 1,333,101 7.8 $ 0.72 1,101,459 7.6 $ 0.69
Schedule of Loans Obligated to Issue Shares	As profiled in the following table, for seven loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Percentage of Loan Defined Shares Issuable Loan Loan Issuance Date Principal Principal Issuable Date Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 September 23, 2020 $ 15,000 0.0652 % December 1, 2020 Weekly Loan 4 September 25, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 5 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 6 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly Loan 7 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Weekly

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net proceeds from additional convertible and non-convertible debt	$ 7,779,538
Proceeds from Issuance of Convertible Preferred Stock	1,015,000	$ 150,000
Cash and cash equivalents	132,311	$ 18,540
Series AA Preferred Stock [Member]
Proceeds from Issuance of Convertible Preferred Stock	$ 1,015,000

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Revenue	$ 2,002,365	$ 1,220,591
Hardware [Member]
Product Information [Line Items]
Revenue	1,104,000	568,000
Consumables [Member]
Product Information [Line Items]
Revenue	274,000	205,000
Contract Research Services [Member]
Product Information [Line Items]
Revenue	268,000	193,000
Agrochem Products [Member]
Product Information [Line Items]
Revenue	29,000
Sample Preparation Accessories [Member]
Product Information [Line Items]
Revenue	140,000	116,000
Technical Support/Extended Service Contracts [Member]
Product Information [Line Items]
Revenue	119,000	96,000
Shipping and Handling [Member]
Product Information [Line Items]
Revenue	51,000	29,000
Other [Member]
Product Information [Line Items]
Revenue	17,000	14,000
Transferred at a Point In Time [Member]
Product Information [Line Items]
Revenue	1,674,000	978,000
Transferred Over At Time [Member]
Product Information [Line Items]
Revenue	328,000	243,000
North America [Member]
Product Information [Line Items]
Revenue	1,179,000	844,000
Europe [Member]
Product Information [Line Items]
Revenue	289,000	88,000
Asia [Member]
Product Information [Line Items]
Revenue	$ 534,000	$ 289,000

Schedule of Contract Balances (

Schedule of Contract Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Receivables, which are included in ‘Accounts Receivable’	$ 155	$ 131
Contract liabilities (deferred revenue)	$ 41	$ 67

Schedule of Future Related to P

Schedule of Future Related to Performance Obligations (Details)	Dec. 31, 2021USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended warranty service	$ 41
2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended warranty service	37
2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended warranty service	$ 4

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Raw materials	$ 296,892	$ 217,682
Finished goods	1,193,158	717,581
Inventory reserve	(342,496)	(342,496)
Total	$ 1,147,554	$ 592,767

Schedule of Customer Concentrat

Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Top Five Customers [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	44.00%	33.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	82.00%	89.00%
Federal Agencies [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	6.00%	4.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage	5.00%	10.00%

Schedule of Computation of Loss

Schedule of Computation of Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Net loss attributable to common shareholders	$ (22,685,459)	$ (17,584,710)
Weighted average common shares outstanding	6,636,523	3,304,187
Loss per common share - basic and diluted	$ (3.42)	$ (5.32)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	31,921,119	28,808,263
Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	1,333,101	1,355,901
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	5,232,118	4,474,868
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	16,207,108	14,434,702
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	26,857	26,857
Series H Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	33,334	33,334
Series H2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	115,267	115,267
Series K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	229,334	229,334
Series AA Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,649,000	8,043,000

Summary of Assumptions for Gran

Summary of Assumptions for Grants of Stock Options (Details) - CEO, other Officers and Employees [Member]	12 Months Ended
	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 years
Expected volatility	155.02%
Risk-free interest rate	0.62%
Forfeiture rate	5.00%
Expected dividend yield	0.00%

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total stock-based compensation expense	$ 254,615	$ 488,792
Research and Development Expense [Member]
Total stock-based compensation expense	128,094	141,202
Selling and Marketing Expense [Member]
Total stock-based compensation expense	22,233	34,142
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 104,288	$ 313,448

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable, Impaired [Line Items]
Total Financial Assets	$ 59,976	$ 517,001
Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Impaired [Line Items]
Total Financial Assets	59,976	517,001
Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Impaired [Line Items]
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Impaired [Line Items]
Total Financial Assets
Equity Securities [Member]
Financing Receivable, Impaired [Line Items]
Total Financial Assets	59,976	517,001
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Impaired [Line Items]
Total Financial Assets	59,976	517,001
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Impaired [Line Items]
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Impaired [Line Items]
Total Financial Assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Intangible assets	$ 403,846	$ 490,385
Forfeiture rate		5.00%
Fair value of stock options awarded	49,135	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 140,455
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	1 year 1 month 2 days
Advertising costs	$ 17,594	$ 19,572
Everest [Member]
Sale of stock number of shares received	100,250
Number of common stock shares exchanged during the period	33,334
Nexity Global SA [Member]
Sale of stock number of shares received	100,250
Investment Owned, at Fair Value	$ 59,976
Unrealized losses	$ 457,025

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Laboratory and manufacturing equipment	$ 353,379	$ 240,670
Office equipment	194,999	184,763
Leasehold improvements	25,248	25,248
PCT collaboration, demonstration and leased systems	53,098	53,098
Total property and equipment	626,724	503,779
Less accumulated depreciation	(510,878)	(487,289)
Net book value	$ 115,846	$ 16,490

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 23,589	$ 40,763

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
BaroFold Patents	$ 750,000	$ 750,000
Less accumulated amortization	(346,154)	(259,615)
Net book value	$ 403,846	$ 490,385

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 86,539	$ 86,538
Intangible assets amortization of straight line period	9 years
Amortization expense, year one	$ 80,000
Amortization expense, year two	80,000
Amortization expense, year three	80,000
Amortization expense, year four	80,000
Amortization expense, year five	80,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 80,000

Retirement Plan (Details Narrat

Retirement Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Payment for Pension Benefits	$ 11,752	$ 13,436

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Long term deferred taxes, Inventories	$ 93,570	$ 93,570
Long term deferred taxes, Accrued expenses	91,792	156,699
Long term deferred taxes, Other	15,169	15,169
Long term deferred taxes, Non-cash, stock-based compensation, nonqualified	814,202	1,206,664
Long term deferred taxes, Impairment loss on investment	104,609	104,609
Long term deferred taxes, Operating loss carry forwards and tax credits	28,435,535	22,062,690
Long term deferred taxes, Less: valuation allowance	(29,554,877)	(23,639,401)
Long term deferred taxes, Total net deferred tax assets

Schedule of U.S. Federal Statut

Schedule of U.S. Federal Statutory Tax Rate to Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory U.S. Federal tax rate	21.00%	21.00%
Permanent differences	0.00%	0.00%
State tax expense	0.00%	0.00%
Refundable AMT and R&D tax credit	0.00%	0.00%
Valuation allowance	21.00%	21.00%
Effective tax rate

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards		$ 57,298,328
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 98,933,918
Operating loss carry-forwards expire term	2022 through 2037
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry-forwards expire term	2022
Income Tax Examination, Description	Under the Tax Reform Act, NOL’s generated after December 31, 2017 can offset only 80% of a corporation’s taxable income in any year.
Deferred Tax Assets, Tax Credit Carryforwards	$ 1,288,308
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 94,663,553
Operating loss carry-forwards expire term	2031 through 2038
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry-forwards expire term	2023 through 2034
Deferred Tax Assets, Tax Credit Carryforwards	$ 306,425

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Dec. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 230,318
2023	149,299
2024	64,393
2025	66,969
2026	51,778
Thereafter
Total	$ 562,757

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)	Aug. 09, 2021	Apr. 30, 2012	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease expire date			Dec. 30, 2023
Annua cost of living payment			$ 7,282
Lease expiration term	On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term.		The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term
Right-of-use asset			$ 395,565	$ 221,432
Expenses			6,187,512	5,806,378
Battelle Memorial Institute [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Minimum royalty fee					$ 5,000	$ 4,000	$ 3,000	$ 2,000	$ 1,200
Target Discovery Inc [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Minimum royalty fee			60,000	60,000
Payments for Other Fees		$ 1,400
Professional and Contract Services Expense		$ 2,000
Expenses			82,800	$ 86,800
Medford lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Right-of-use asset			221,432
Lease liability			$ 221,432
Estimated borrowing rate			12.00%
Sparks lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease liability			$ 239,327
Estimated borrowing rate			12.00%
Corporate Office [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease monthly payments			$ 6,950
Lease expire date			Dec. 31, 2022

Schedule of Convertible Debts a

Schedule of Convertible Debts and Outstanding Balances (Details)		12 Months Ended
		Dec. 31, 2021USD ($)Integer$ / shares	Dec. 31, 2020USD ($)
Line of Credit Facility [Line Items]
Convertible Debt		$ 12,839,813	$ 7,545,670
Debt conversion original debt amount		1,705,455
Debt Instrument, Fee Amount		8,500
Debt instrument beneficial conversion amount		1,320,331
Convertible debt		12,839,813	7,545,670
Debt instrument fee amount		$ 8,500
Debt instrument convertible stock price | $ / shares		$ 2.50
Trading days | Integer		5
Fixed Rate Convertible Notes [Member]
Line of Credit Facility [Line Items]
Convertible Debt		$ 14,376,462
Debt conversion original debt amount		1,661,225
Debt Instrument, Fee Amount		1,039,250
Debt instrument beneficial conversion amount		9,508,836
Convertible debt		14,376,462
Debt instrument fee amount		$ 1,039,250
Auctus One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 380,000
Convertible Debt		166,703
Debt conversion original debt amount		$ 15,200
Debt conversion interest rate percentage		8.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 15,200
Debt instrument beneficial conversion amount		$ 332,407
Inception Date	[1],[2]	May 17, 2018
Convertible debt		$ 166,703
Debt instrument fee amount		$ 15,200
James Gathard [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 50,000
Convertible Debt		50,000
Debt conversion original debt amount		$ 2,500
Debt conversion interest rate percentage		24.00%
Debt conversion price | $ / shares		$ 7.50
Debt Instrument, Fee Amount		$ 2,500
Debt instrument beneficial conversion amount
Inception Date	[2],[3]	Jan. 3, 2019
Convertible debt		$ 50,000
Debt instrument fee amount		$ 2,500
Auctus Two [Member]
Line of Credit Facility [Line Items]
Debt conversion term		9 months
Debt Instrument, Face Amount		$ 500,000
Convertible Debt		302,484
Debt conversion original debt amount
Debt conversion interest rate percentage		8.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 40,500
Debt instrument beneficial conversion amount		$ 70,631
Inception Date	[1],[2]	Jun. 4, 2019
Convertible debt		$ 302,484
Debt instrument fee amount		$ 40,500
LGCapital One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 115,000
Convertible Debt		115,000
Debt conversion original debt amount
Debt conversion interest rate percentage		4.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 5,750
Debt instrument beneficial conversion amount		$ 15,460
Inception Date	[1],[2]	Jul. 19, 2019
Convertible debt		$ 115,000
Debt instrument fee amount		$ 5,750
LG Capital Two [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 78,750
Convertible Debt		78,750
Debt conversion original debt amount
Debt conversion interest rate percentage		4.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 3,750
Debt instrument beneficial conversion amount		$ 13,759
Inception Date	[1],[2]	Sep. 27, 2019
Convertible debt		$ 78,750
Debt instrument fee amount		$ 3,750
LG Capital Three [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 78,750
Convertible Debt		78,750
Debt conversion original debt amount
Debt conversion interest rate percentage		4.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 3,750
Debt instrument beneficial conversion amount
Inception Date	[1],[2]	Oct. 24, 2019
Convertible debt		$ 78,750
Debt instrument fee amount		$ 3,750
Clay Loan One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 385,000
Convertible Debt		320,000
Debt conversion original debt amount		$ 35,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 35,000
Debt instrument beneficial conversion amount		$ 90,917
Inception Date	[2]	Nov. 15, 2019
Convertible debt		$ 320,000
Debt instrument fee amount		$ 35,000
Clay Loan Two [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 330,000
Convertible Debt		330,000
Debt conversion original debt amount		$ 30,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 30,000
Debt instrument beneficial conversion amount		$ 91,606
Inception Date	[2]	Jan. 2, 2020
Convertible debt		$ 330,000
Debt instrument fee amount		$ 30,000
Clay Loan Three [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 247,500
Convertible Debt		247,500
Debt conversion original debt amount		$ 22,500
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 22,500
Debt instrument beneficial conversion amount		$ 89,707
Inception Date	[2]	Jan. 24, 2020
Convertible debt		$ 247,500
Debt instrument fee amount		$ 22,500
Clay Loan Four [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 363,000
Convertible Debt		363,000
Debt conversion original debt amount		$ 33,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 33,000
Debt instrument beneficial conversion amount		$ 297,000
Inception Date	[2]	Jan. 29, 2020
Convertible debt		$ 363,000
Debt instrument fee amount		$ 33,000
Clay Loan Five [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 275,000
Convertible Debt		275,000
Debt conversion original debt amount		$ 25,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 25,000
Debt instrument beneficial conversion amount		$ 225,000
Inception Date	[2]	Feb. 12, 2020
Convertible debt		$ 275,000
Debt instrument fee amount		$ 25,000
Clay Loan Six [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 165,000
Convertible Debt		165,000
Debt conversion original debt amount		$ 15,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 15,000
Debt instrument beneficial conversion amount		$ 135,000
Inception Date	[2]	Feb. 19, 2020
Convertible debt		$ 165,000
Debt instrument fee amount		$ 15,000
Clay Loan Seven [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 330,000
Convertible Debt		330,000
Debt conversion original debt amount		$ 30,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 30,000
Debt instrument beneficial conversion amount		$ 232,810
Inception Date	[2]	Mar. 11, 2020
Convertible debt		$ 330,000
Debt instrument fee amount		$ 30,000
Clay Loan Eight [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 165,000
Convertible Debt		165,000
Debt conversion original debt amount		$ 15,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 15,000
Debt instrument beneficial conversion amount		$ 60,705
Inception Date	[2]	Mar. 13, 2020
Convertible debt		$ 165,000
Debt instrument fee amount		$ 15,000
Clay Loan Nine [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 111,100
Convertible Debt		111,100
Debt conversion original debt amount		$ 10,100
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 10,100
Debt instrument beneficial conversion amount		$ 90,900
Inception Date	[2]	Mar. 26, 2020
Convertible debt		$ 111,100
Debt instrument fee amount		$ 10,100
Clay Loan Ten [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 276,100
Convertible Debt		276,100
Debt conversion original debt amount		$ 25,100
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 25,000
Debt instrument beneficial conversion amount		$ 221,654
Inception Date	[2]	Apr. 8, 2020
Convertible debt		$ 276,100
Debt instrument fee amount		$ 25,000
Clay Loan Eleven [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 143,750
Convertible Debt		143,750
Debt conversion original debt amount		$ 18,750
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 96,208
Inception Date	[2]	Apr. 17, 2020
Convertible debt		$ 143,750
Debt instrument fee amount
Clay Loan Twelve [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 546,250
Convertible Debt		546,250
Debt conversion original debt amount		$ 71,250
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 47,500
Debt instrument beneficial conversion amount		$ 427,500
Inception Date	[2]	Apr. 30, 2020
Convertible debt		$ 546,250
Debt instrument fee amount		$ 47,500
Clay Loan Thirteen [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 460,000
Convertible Debt		460,000
Debt conversion original debt amount		$ 60,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 40,000
Debt instrument beneficial conversion amount		$ 360,000
Inception Date	[2]	May 6, 2020
Convertible debt		$ 460,000
Debt instrument fee amount		$ 40,000
Clay Loan Fourteen [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 546,250
Convertible Debt		221,250
Debt conversion original debt amount		$ 46,250
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 35,500
Debt instrument beneficial conversion amount		$ 439,500
Inception Date	[2]	May 18, 2020
Convertible debt		$ 221,250
Debt instrument fee amount		$ 35,500
Clay Loan Fifteen [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 902,750
Convertible Debt		652,750
Debt conversion original debt amount		$ 92,750
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 58,900
Debt instrument beneficial conversion amount		$ 708,500
Inception Date	[2]	Jun. 2, 2020
Convertible debt		$ 652,750
Debt instrument fee amount		$ 58,900
Clay Loan Sixteen [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 57,500
Convertible Debt		57,500
Debt conversion original debt amount		$ 7,500
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 5,000
Debt instrument beneficial conversion amount		$ 45,000
Inception Date	[2]	Jun. 12, 2020
Convertible debt		$ 57,500
Debt instrument fee amount		$ 5,000
Clay Loan Seventeen [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 138,000
Convertible Debt		138,000
Debt conversion original debt amount		$ 18,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 12,000
Debt instrument beneficial conversion amount		$ 108,000
Inception Date	[2]	Jun. 22, 2020
Convertible debt		$ 138,000
Debt instrument fee amount		$ 12,000
Struve One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 586,500
Convertible Debt		586,500
Debt conversion original debt amount		$ 76,500
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 51,000
Debt instrument beneficial conversion amount		$ 400,234
Inception Date	[2]	Jul. 7, 2020
Convertible debt		$ 586,500
Debt instrument fee amount		$ 51,000
Struve Two [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 362,250
Convertible Debt		362,250
Debt conversion original debt amount		$ 47,250
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 31,500
Debt instrument beneficial conversion amount		$ 185,698
Inception Date	[2]	Jul. 17, 2020
Convertible debt		$ 362,250
Debt instrument fee amount		$ 31,500
Struve Three [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 345,000
Convertible Debt		345,000
Debt conversion original debt amount		$ 45,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 30,000
Debt instrument beneficial conversion amount		$ 241,245
Inception Date	[2]	Jul. 29, 2020
Convertible debt		$ 345,000
Debt instrument fee amount		$ 30,000
Hersh kowitz [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 115,000
Convertible Debt		115,000
Debt conversion original debt amount		$ 15,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 10,000
Debt instrument beneficial conversion amount		$ 24,875
Inception Date	[2],[4]	Jul. 21, 2020
Convertible debt		$ 115,000
Debt instrument fee amount		$ 10,000
Struve Four [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 762,450
Convertible Debt		462,450
Debt conversion original debt amount		$ 69,450
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 66,300
Debt instrument beneficial conversion amount		$ 580,124
Inception Date	[2]	Aug. 14, 2020
Convertible debt		$ 462,450
Debt instrument fee amount		$ 66,300
Struve Five [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 391,000
Convertible Debt		391,000
Debt conversion original debt amount		$ 51,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 34,000
Debt instrument beneficial conversion amount		$ 231,043
Inception Date	[2]	Sep. 10, 2020
Convertible debt		$ 391,000
Debt instrument fee amount		$ 34,000
Hackett [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 345,000
Convertible Debt		345,000
Debt conversion original debt amount		$ 45,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 30,000
Debt instrument beneficial conversion amount		$ 66,375
Inception Date	[2],[4]	Sep. 21, 2020
Convertible debt		$ 345,000
Debt instrument fee amount		$ 30,000
Cove [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 115,000
Convertible Debt		15,000
Debt conversion original debt amount		$ 15,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 10,000
Debt instrument beneficial conversion amount		$ 20,500
Inception Date	[2],[4]	Sep. 23, 2020
Convertible debt		$ 15,000
Debt instrument fee amount		$ 10,000
M Hershkowitz One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 115,000
Convertible Debt		115,000
Debt conversion original debt amount		$ 15,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 19,125
Inception Date	[2],[4]	Sep. 25, 2020
Convertible debt		$ 115,000
Debt instrument fee amount
Clay Loan Eighteen [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 299,000
Convertible Debt		299,000
Debt conversion original debt amount		$ 39,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 26,000
Debt instrument beneficial conversion amount		$ 197,882
Inception Date	[2]	Dec. 3, 2020
Convertible debt		$ 299,000
Debt instrument fee amount		$ 26,000
M Hershkowitz Two [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 115,000
Convertible Debt		115,000
Debt conversion original debt amount		$ 15,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 10,000
Debt instrument beneficial conversion amount		$ 18,875
Inception Date	[2],[4]	Oct. 22, 2020
Convertible debt		$ 115,000
Debt instrument fee amount		$ 10,000
Struve Six [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 230,000
Convertible Debt		230,000
Debt conversion original debt amount		$ 30,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 20,000
Debt instrument beneficial conversion amount		$ 180,000
Inception Date	[2]	Feb. 17, 2021
Convertible debt		$ 230,000
Debt instrument fee amount		$ 20,000
Rosa Blum [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 55,000
Convertible Debt		55,000
Debt conversion original debt amount		$ 5,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 36,431
Inception Date	[2]	Mar. 23, 2021
Convertible debt		$ 55,000
Debt instrument fee amount
Downey [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 54,625
Convertible Debt		4,625
Debt conversion original debt amount		$ 7,125
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount
Inception Date		May 24, 2021
Convertible debt		$ 4,625
Debt instrument fee amount
Clay Loan Nineteen [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 402,500
Convertible Debt		402,500
Debt conversion original debt amount		$ 52,500
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 35,000
Debt instrument beneficial conversion amount		$ 312,551
Inception Date		May 6, 2021
Convertible debt		$ 402,500
Debt instrument fee amount		$ 35,000
Clay Loan Twenty [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 230,000
Convertible Debt		230,000
Debt conversion original debt amount		$ 30,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 20,000
Debt instrument beneficial conversion amount		$ 144,760
Inception Date		Jun. 17, 2021
Convertible debt		$ 230,000
Debt instrument fee amount		$ 20,000
Clay Loan Twenty One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 977,500
Convertible Debt		977,500
Debt conversion original debt amount		$ 127,500
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 773,802
Inception Date		Jun. 25, 2021
Convertible debt		$ 977,500
Debt instrument fee amount
Hoffman [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 180,000
Convertible Debt		30,000
Debt conversion original debt amount		$ 30,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 15,000
Debt instrument beneficial conversion amount		$ 25,824
Inception Date		May 20, 2021
Convertible debt		$ 30,000
Debt instrument fee amount		$ 15,000
Harding [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 50,000
Convertible Debt		50,000
Debt conversion original debt amount		$ 1,500
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 7,948
Inception Date		Jun. 3, 2021
Convertible debt		$ 50,000
Debt instrument fee amount
AJB Capital [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 350,000
Convertible Debt		350,000
Debt conversion original debt amount		$ 35,000
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (6)
Debt Instrument, Fee Amount		$ 22,750
Debt instrument beneficial conversion amount		$ 267,250
Inception Date		Jun. 28, 2021
Convertible debt		$ 350,000
Debt instrument fee amount		$ 22,750
Clay Loan Twenty Two[Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 115,000
Convertible Debt		115,000
Debt conversion original debt amount		$ 15,000
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 10,000
Debt instrument beneficial conversion amount		$ 90,000
Inception Date		Jul. 3, 2021
Convertible debt		$ 115,000
Debt instrument fee amount		$ 10,000
James Lederer [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 260,000
Convertible Debt		260,000
Debt conversion original debt amount		$ 10,000
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 89,640
Inception Date		Jul. 1, 2021
Convertible debt		$ 260,000
Debt instrument fee amount
Brandon Williams [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 125,000
Convertible Debt		125,000
Debt conversion original debt amount
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 42,031
Inception Date		Jul. 6, 2021
Convertible debt		$ 125,000
Debt instrument fee amount
Patrick Gruhn [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 125,000
Convertible Debt		125,000
Debt conversion original debt amount
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 42,031
Inception Date		Jul. 6, 2021
Convertible debt		$ 125,000
Debt instrument fee amount
James Downey [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 100,000
Convertible Debt		100,000
Debt conversion original debt amount		$ 5,000
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (7)
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 57,716
Inception Date	[2]	Jul. 15, 2021
Convertible debt		$ 100,000
Debt instrument fee amount
Kimberly Stewart [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 50,000
Convertible Debt		50,000
Debt conversion original debt amount		$ 2,000
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 3
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 40,806
Inception Date		Jul. 16, 2021
Convertible debt		$ 50,000
Debt instrument fee amount
Target [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 306,250
Convertible Debt		306,250
Debt conversion original debt amount		$ 56,250
Debt conversion interest rate percentage		(3.00%)
Debt conversion price | $ / shares		$ (8)
Debt Instrument, Fee Amount		$ 22,500
Debt instrument beneficial conversion amount		$ 227,500
Inception Date	[5]	Jul. 16, 2021
Convertible debt		$ 306,250
Debt instrument fee amount		$ 22,500
622 Capital [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 306,250
Convertible Debt		306,250
Debt conversion original debt amount		$ 56,250
Debt conversion interest rate percentage		(3.00%)
Debt conversion price | $ / shares		$ (8)
Debt Instrument, Fee Amount		$ 12,500
Debt instrument beneficial conversion amount		$ 237,500
Inception Date	[5]	Jul. 16, 2021
Convertible debt		$ 306,250
Debt instrument fee amount		$ 12,500
NCorner [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 122,500
Convertible Debt		122,500
Debt conversion original debt amount		$ 22,500
Debt conversion interest rate percentage		(3.00%)
Debt conversion price | $ / shares		$ (8)
Debt Instrument, Fee Amount		$ 5,000
Debt instrument beneficial conversion amount		$ 95,000
Inception Date	[5]	Jul. 16, 2021
Convertible debt		$ 122,500
Debt instrument fee amount		$ 5,000
Clay Loan Twenty Three [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 189,750
Convertible Debt		189,750
Debt conversion original debt amount		$ 24,750
Debt conversion interest rate percentage		10.00%
Debt conversion price | $ / shares		$ (9)
Debt Instrument, Fee Amount		$ 16,500
Debt instrument beneficial conversion amount		$ 148,500
Inception Date	[2]	Aug. 31, 2021
Convertible debt		$ 189,750
Debt instrument fee amount		$ 16,500
John Hollister [Member]
Line of Credit Facility [Line Items]
Debt conversion term		8 months
Debt Instrument, Face Amount		$ 78,000
Convertible Debt		78,000
Debt conversion original debt amount		$ 3,000
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (7)
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 40,449
Inception Date		Sep. 8, 2021
Convertible debt		$ 78,000
Debt instrument fee amount
KBJA [Member]
Line of Credit Facility [Line Items]
Debt conversion term		8 months
Debt Instrument, Face Amount		$ 100,000
Convertible Debt		100,000
Debt conversion original debt amount		$ 4,000
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (7)
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 43,520
Inception Date		Sep. 10, 2021
Convertible debt		$ 100,000
Debt instrument fee amount
Patrick Gruhn One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 250,000
Convertible Debt		250,000
Debt conversion original debt amount		$ 12,500
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (7)
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 108,801
Inception Date	[2]	Sep. 15, 2021
Convertible debt		$ 250,000
Debt instrument fee amount
Brandon Williams One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 250,000
Convertible Debt		250,000
Debt conversion original debt amount		$ 12,500
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (7)
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 112,337
Inception Date		Sep. 16, 2021
Convertible debt		$ 250,000
Debt instrument fee amount
James Downey One [Member]
Line of Credit Facility [Line Items]
Debt conversion term		8 months
Debt Instrument, Face Amount		$ 125,000
Convertible Debt		125,000
Debt conversion original debt amount		$ 6,250
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (7)
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 61,876
Inception Date		Sep. 24, 2021
Convertible debt		$ 125,000
Debt instrument fee amount
Harlon Holdings [Member]
Line of Credit Facility [Line Items]
Debt conversion term		6 months
Debt Instrument, Face Amount		$ 250,000
Convertible Debt		250,000
Debt conversion original debt amount		$ 37,500
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (7)
Debt Instrument, Fee Amount		$ 30,000
Debt instrument beneficial conversion amount
Inception Date		Sep. 15, 2021
Convertible debt		$ 250,000
Debt instrument fee amount		$ 30,000
M Hershkowitz Three [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 189,750
Convertible Debt		189,750
Debt conversion original debt amount		$ 24,750
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount		$ 16,500
Debt instrument beneficial conversion amount		$ 87,332
Inception Date	[4]	Oct. 21, 2021
Convertible debt		$ 189,750
Debt instrument fee amount		$ 16,500
M Hershkowitz Four [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 189,750
Convertible Debt		189,750
Debt conversion original debt amount		$ 24,750
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ 2.50
Debt Instrument, Fee Amount
Debt instrument beneficial conversion amount		$ 96,991
Inception Date	[4]	Nov. 1, 2021
Convertible debt		$ 189,750
Debt instrument fee amount
Sixth St Lending [Member]
Line of Credit Facility [Line Items]
Debt conversion term		12 months
Debt Instrument, Face Amount		$ 169,500
Convertible Debt		169,500
Debt conversion original debt amount		$ 19,500
Debt conversion interest rate percentage		12.00%
Debt conversion price | $ / shares		$ (10)
Debt Instrument, Fee Amount		$ 3,750
Debt instrument beneficial conversion amount
Inception Date		Dec. 7, 2021
Convertible debt		$ 169,500
Debt instrument fee amount		$ 3,750
[1]	The Company and lender have agreed to the extension of the Standstill and Forbearance agreements (as described below).
[2]	The Note is past due. The Company and the lender are negotiating in good faith to extend the loan.
[3]	During the year ended December 31, 2020 the Company entered into Rate Modification Agreements with these lenders. In these agreements five lenders agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate.
[4]	The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date.
[5]	Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and Interest rate is. 18.4

Schedule of Convertible Debts_2

Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical) - $ / shares	Dec. 23, 2020	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument, description	we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.	Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $2.50 per share or 90% of the lowest trading price over the previous 20 days. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion
Debt instrument, convertible price per shares		$ 2.50
Debt instrument lowest trading price		90.00%
Debt instrument lowest trading price		25.00%
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible price per shares		$ 2.50
PBI Agrochem, Inc [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		18.40%

Summary of Changes in Convertib

Summary of Changes in Convertible Debt and Revolving Note Payable, Net of Unamortized Discounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Balance at January 1,	$ 7,545,670
Issuance of convertible debt, face value	6,406,375
Deferred financing cost	(892,125)
Beneficial conversion feature on convertible note	(1,320,331)
Debt discount from shares and warrants issued with debt	(2,050,264)
Conversion of debt into equity	(1,705,455)
Payments	(1,833,295)
Accretion of interest and amortization of debt discount to interest expense through December 31	6,689,238
Convertible Debt	12,839,813	$ 7,545,670
Less: current portion	12,839,813	$ 7,545,670
Convertible debt, long-term portion

Schedule of Merchant Agreements

Schedule of Merchant Agreements (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 525,000	$ 300,000
Purchased Amount	686,250	413,700
Outstanding Balance	398,910	248,968
Debt Instrument, Fee Amount	8,500
Merchant Agreements One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	400,000	200,000
Purchased Amount	520,000	275,800
Outstanding Balance	$ 390,120	$ 163,955
Debt Instrument, Frequency of Periodic Payment	Weekly	Daily
Debt Instrument, Periodic Payment	$ 11,305	$ 1,724
Debt Instrument, Fee Amount	$ 6,000
Inception date	Dec. 21, 2021	Nov. 5, 2020
Merchant Agreements Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 125,000	$ 100,000
Purchased Amount	166,250	137,900
Outstanding Balance	$ 8,790	$ 85,013
Debt Instrument, Frequency of Periodic Payment	Daily	Daily
Debt Instrument, Periodic Payment	$ 1,279	$ 985
Debt Instrument, Fee Amount	$ 2,500
Inception date	Jul. 6, 2021	Nov. 19, 2020

Convertible Debt and Other De_3

Convertible Debt and Other Debt (Details Narrative) - USD ($)

Sep. 25, 2021

Sep. 25, 2020

Oct. 11, 2019

Oct. 01, 2019

Sep. 30, 2021

Feb. 28, 2020

Dec. 31, 2021

Dec. 30, 2021

Dec. 31, 2020

Jun. 30, 2021

Apr. 16, 2021

Mar. 31, 2021

Short-term Debt [Line Items]

Proceeds from Convertible Debt

$ 5,514,250

$ 8,296,800

Debt Instrument, Term

3 years

Debt Instrument, Convertible, Beneficial Conversion Feature

1,320,331

Convertible debt

12,839,813

7,545,670

Debt Instrument, Unamortized Discount

1,536,649

3,948,167

Repayments of convertible debt

$ 134,805

1,833,295

2,857,007

Debt Instrument, Fee Amount

8,500

Gain (Loss) on Extinguishment of Debt

(130,279)

(1,036,638)

Repayments of Debt

$ 1,833,295

Common stock issued for debt settlement, shares

2,883,282

Repayments of Related Party Debt

$ 354,600

$ 199,200

Small Business Administration [Member]

Short-term Debt [Line Items]

Debt Instrument, Term

2 years

Debt Instrument, Interest Rate, Stated Percentage

1.00%

Debt Instrument, Face Amount

367,039

$ 527,039

Debt Instrument, Decrease, Forgiveness

367,039

Standstill and Forbearance Agreements [Member]

Short-term Debt [Line Items]

Debt Instrument, Fee Amount

1,470,000

Merchant Agreement [Member]

Short-term Debt [Line Items]

Amortization of Debt Discount (Premium)

49,564

318,641

Debt Instrument, Unamortized Discount

0

$ 0

Eonomic Injury Disaster Loan Program [Member]

Short-term Debt [Line Items]

Debt Instrument, Term

30 years

Debt Instrument, Interest Rate, Stated Percentage

3.75%

Debt Instrument, Face Amount

$ 150,000

Debt Instrument, Periodic Payment

731

One Lender [Member]

Short-term Debt [Line Items]

Convertible debt

9,400,000

Lender [Member]

Short-term Debt [Line Items]

Convertible debt

$ 14,400,000

Common stock issued for debt settlement, shares

140,200

Lenders [Member]

Short-term Debt [Line Items]

Warrants and Rights Outstanding, Term

3 years

Warrants exercise price per share

$ 3.5

Lenders [Member] | Standstill and Forbearance Agreements [Member]

Short-term Debt [Line Items]

Convertible debt

$ 1,100,000

$ 469,000

Debt Instrument, Face Amount

$ 1,570,000

Warrant [Member]

Short-term Debt [Line Items]

Convertible Debt, Fair Value Disclosures

$ 1,400,000

$ 4,900,000

Convertible Common Stock [Member]

Short-term Debt [Line Items]

Debt Instrument, Convertible, Conversion Price

$ 2.50

Convertible Debt, Fair Value Disclosures

$ 646,718

$ 214,419

Minimum [Member] | Merchant Agreements [Member]

Short-term Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.30%

Maximum [Member] | Merchant Agreements [Member]

Short-term Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

14.00%

Convertible Debt [Member]

Short-term Debt [Line Items]

Proceeds from Convertible Debt

$ 5,500,000

8,300,000

Debt Instrument, Convertible, Beneficial Conversion Feature

1,300,000

1,800,000

Amortization of Debt Discount (Premium)

6,689,238

5,118,222

Debt Instrument, Unamortized Discount

$ 1,536,649

$ 3,948,167

Convertible Debt [Member] | Minimum [Member]

Short-term Debt [Line Items]

Debt Instrument, Term

6 months

6 months

Debt Instrument, Interest Rate, Stated Percentage

10.00%

10.00%

Debt Instrument, Convertible, Conversion Price

$ 0.0250

Convertible Debt [Member] | Maximum [Member]

Short-term Debt [Line Items]

Debt Instrument, Term

12 months

12 months

Debt Instrument, Interest Rate, Stated Percentage

18.00%

18.00%

Debt Instrument, Convertible, Conversion Price

$ 0.0300

Convertible Notes [Member]

Short-term Debt [Line Items]

Amortization of Debt Discount (Premium)

$ 5,118,222

Five Notes [Member] | Standstill and Forbearance Agreements [Member]

Short-term Debt [Line Items]

Repayments of convertible debt

$ 741,500

Five Notes [Member] | Three Lenders [Member] | Standstill and Forbearance Agreements [Member]

Short-term Debt [Line Items]

Repayments of convertible debt

$ 827,500

New Loan [Member]

Short-term Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Interest Rate Terms

According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications

Gain (Loss) on Extinguishment of Debt

$ 1,795,150

3,575,878

Non-Convertible Loans [Member] | Private Investor [Member]

Short-term Debt [Line Items]

Debt Instrument, Term

1 month

Debt Instrument, Interest Rate, Stated Percentage

2.00%

Debt Instrument, Face Amount

$ 691,500

691,500

Proceeds from Loans

$ 25,000

$ 966,500

$ 463,500

Non-Convertible Loans [Member] | Holder [Member]

Short-term Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Proceeds from Loans

$ 170,000

Common stock issued for debt settlement, shares

1,200

Non-Convertible Loans [Member] | Warrant [Member] | Private Investor [Member]

Short-term Debt [Line Items]

Number of warrants issued

150,000

Warrants and Rights Outstanding, Term

5 years

Warrants exercise price per share

$ 3.50

Repayments of Debt

$ 275,000

Fair Value Adjustment of Warrants

$ 185,660

Non Convertible Loan [Member] | Series AA Preferred Stock [Member] | Private Investor [Member]

Short-term Debt [Line Items]

Number of warrants issued

17,000

Warrants and Rights Outstanding, Term

5 years

Warrants exercise price per share

$ 3.50

Common stock issued for debt settlement, shares

17

Short-term Non-Convertible Loan [Member]

Short-term Debt [Line Items]

Proceeds from Short-term Debt

$ 254,600

Repayments of Related Party Debt

354,600

Debt conversion principal amount

66,000

Debt conversion interest amount

$ 107,625

Short-term Non-Convertible Loan [Member] | Series AA Preferred Stock [Member]

Short-term Debt [Line Items]

Number of warrants issued

69,450

Warrants and Rights Outstanding, Term

5 years

Warrants exercise price per share

$ 3.50

Common stock issued for debt settlement, shares

69.5

Short-term Non-Convertible Loan [Member] | Minimum [Member]

Short-term Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Short-term Non-Convertible Loan [Member] | Maximum [Member]

Short-term Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

15.00%

Schedule of Concerning Options

Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	15,790,603	11,289,336
Exercisable, Beginning balance	15,302,830	10,148,543
Shares, Granted	2,259,408	4,925,031
Shares, Exercised	(208,911)
Shares, Expired	(275,502)	(383,363)
Shares, Forfeited	(25,389)	(40,401)
Shares, Ending balance	17,540,209	15,790,603
Exercisable, Ending balance	17,308,567	15,302,830
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	1,355,901	1,396,302
Weighted average price per share, Beginning balance	$ 0.71	$ 0.69
Shares, Granted	24,000
Weighted average price per share, Granted	$ 2.17
Shares, Exercised	(21,411)
Weighted average price per share, Exercised	$ 0.69
Shares, Expired
Weighted average price per share, Expired
Shares, Forfeited	(25,389)	(40,401)
Weighted average price per share, Forfeited	$ 0.69	$ 0.78
Shares, Ending balance	1,333,101	1,355,901
Weighted average price per share, Ending balance	$ 0.72	$ 0.71
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	14,434,702	9,893,034
Weighted average price per share, Beginning balance	$ 3.50	$ 3.52
Shares, Granted	2,235,408	4,925,031
Weighted average price per share, Granted	$ 3.57	$ 3.50
Shares, Exercised	(187,500)
Weighted average price per share, Exercised	$ 3.50
Shares, Expired	(275,502)	(383,363)
Weighted average price per share, Expired	$ 3.50	$ 4.01
Shares, Forfeited
Weighted average price per share, Forfeited
Shares, Ending balance	16,207,108	14,434,702
Weighted average price per share, Ending balance	$ 3.50	$ 3.50

Schedule of Share-based Compens

Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,333,101
Options Outstanding, Remaining Contractual Life (In Years)	7 years 9 months 18 days
Options Outstanding, Weighted Average Exercise Price	$ 0.72
Options Exercisable, Number Exercisable | shares	1,101,459
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term	7 years 7 months 6 days
Options Exercisable, Weighted Average Exercise Price	$ 0.69
Exercise Price Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range limit	0.69
Exercise price upper range limit	$ 1
Options Outstanding, Number Outstanding | shares	1,309,101
Options Outstanding, Remaining Contractual Life (In Years)	7 years 8 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 0.69
Options Exercisable, Number Exercisable | shares	1,101,459
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term	7 years 7 months 6 days
Options Exercisable, Weighted Average Exercise Price	$ 0.69
Exercise Price Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range limit	1.01
Exercise price upper range limit	$ 3
Options Outstanding, Number Outstanding | shares	24,000
Options Outstanding, Remaining Contractual Life (In Years)	9 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price	$ 2.17
Options Exercisable, Number Exercisable | shares
Options Exercisable, Weighted Average Exercise Price

Schedule of Loans Obligated to

Schedule of Loans Obligated to Issue Shares (Details) - USD ($)	Dec. 23, 2020	Dec. 31, 2021
Short-term Debt [Line Items]
Shares Issuance Frequency	we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.	Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $2.50 per share or 90% of the lowest trading price over the previous 20 days. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion
Loans 1 [Member]
Short-term Debt [Line Items]
Loan Issuance Date		Jul. 21, 2020
Loan Principal		$ 115,000
Loan Principal Issuable Percent		0.0435%
Defined Date		Sep. 30, 2020
Shares Issuance Frequency		Monthly
Loans 2 [Member]
Short-term Debt [Line Items]
Loan Issuance Date		Sep. 21, 2020
Loan Principal		$ 345,000
Loan Principal Issuable Percent		0.0362%
Defined Date		Nov. 16, 2020
Shares Issuance Frequency		Weekly
Loans 3 [Member]
Short-term Debt [Line Items]
Loan Issuance Date		Sep. 23, 2020
Loan Principal		$ 15,000
Loan Principal Issuable Percent		0.0652%
Defined Date		Dec. 1, 2020
Shares Issuance Frequency		Weekly
Loans 4 [Member]
Short-term Debt [Line Items]
Loan Issuance Date		Sep. 25, 2020
Loan Principal		$ 115,000
Loan Principal Issuable Percent		0.0652%
Defined Date		Dec. 1, 2020
Shares Issuance Frequency		Weekly
Loans 5 [Member]
Short-term Debt [Line Items]
Loan Issuance Date		Oct. 22, 2020
Loan Principal		$ 115,000
Loan Principal Issuable Percent		0.0652%
Defined Date		Dec. 1, 2020
Shares Issuance Frequency		Weekly
Loans six [Member]
Short-term Debt [Line Items]
Loan Issuance Date		Oct. 21, 2021
Loan Principal		$ 189,750
Loan Principal Issuable Percent		0.0435%
Defined Date		Jan. 2, 2022
Shares Issuance Frequency		Weekly
Loans Seven [Member]
Short-term Debt [Line Items]
Loan Issuance Date		Nov. 1, 2021
Loan Principal		$ 189,750
Loan Principal Issuable Percent		0.0435%
Defined Date		Jan. 2, 2022
Shares Issuance Frequency		Weekly

Stockholders_ (Deficit) (Detail

Stockholders’ (Deficit) (Details Narrative) - USD ($)	Sep. 25, 2021	Dec. 23, 2020	May 10, 2017	Dec. 23, 2014	May 20, 2013	Jan. 04, 2013	Nov. 15, 2012	Nov. 11, 2011	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 12, 2013	Dec. 28, 2012
Class of Stock [Line Items]
Number of common stock shares issued, shares									2,883,282
Common stock, par value									$ 0.01	$ 0.01
Warrant issued									36,290
Loss on settlement of liabilities									$ 23,004
Adjusted beneficial conversion feature value for deemed dividend									$ 1,320,331	$ 1,756,311
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									17,540,209	15,790,603	11,289,336
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount									$ 140,455
Stock issuances exercise price									$ 0.72
Number of common stock shares issued for services									333,200
Number of common stock value issued for consulting and investor services									$ 794,562	$ 179,077
Number of shares issued, value									$ 6,665,656	374,550
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,195,996
Common stock convertible loans fair value acquired									$ 2,989,990	$ 2,220,442
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									208,911
[custom:StockIssuedWithDebt]									$ 646,718
Warrants issued for debt settlement									107,275	$ 338,412
Interest Expense, Debt									$ 6,288,529
Debt Instrument, Description		we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.							Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $2.50 per share or 90% of the lowest trading price over the previous 20 days. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion
Issuance fair value [Member]
Class of Stock [Line Items]
Number of common stock shares issued for services										76,800
Number of common stock value issued for consulting and investor services										$ 179,077
Convertible Debt On March 26, 2015
Class of Stock [Line Items]
Number of common stock shares issued, shares										871,309
Number of shares issued, value										$ 2,220,442
Convertible Debt On March 26, 2015
Class of Stock [Line Items]
Number of common stock shares issued, shares										323,260
Number of shares issued, value										$ 629,809
Shares With Fair Value [Member]
Class of Stock [Line Items]
Number of common stock shares issued, shares										66,500
Number of shares issued, value										$ 127,855
Number of shares issued to settle an accrued liability										158,700
Issued in Conjunction with Signing of New Convertible Loans [Member]
Class of Stock [Line Items]
Number of shares issued, value										$ 214,419
Lender [Member]
Class of Stock [Line Items]
Fair value of warrant									$ 600,298
Warrant, shares									400,000
Price per shares									$ 3.50
Lenders [Member]
Class of Stock [Line Items]
Warrants and rights outstanding, term									3 years
Warrants exercise price per share									$ 3.5
Warrants issued									71,042
Warrants issued for debt settlement									$ 107,275
Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount									$ 140,455	$ 304,900
[custom:UnvestedStockOptionsWeightedAveragePeriod]									1 year 1 month 2 days	1 year 7 months 2 days
Share Price									$ 2.31	$ 2.12
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue-0]									$ 2,124,104	$ 1,240,469
Investor Warrants [Member]
Class of Stock [Line Items]
Warrant to purchase shares of common stock									406,000	60,000
Fair value of warrant									$ 509,130	$ 69,580
Warrant [Member]
Class of Stock [Line Items]
Adjusted beneficial conversion feature value for deemed dividend
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									16,207,108	14,434,702	9,893,034
Weighted average remaining contractual term									2 years 4 months 20 days	3 years 1 month 6 days
Intrinsic value									$ 0	$ 0
Number of common stock value issued for consulting and investor services
Number of shares issued, value
Common stock convertible loans fair value acquired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									187,500
[custom:StockIssuedWithDebt]
Warrants issued for debt settlement									$ 107,275	$ 338,412
Common Stock [Member]
Class of Stock [Line Items]
Number of common stock shares issued, shares	37,000									188,778
Warrant issued									1,146,945
Adjusted beneficial conversion feature value for deemed dividend
Stock issuances exercise price									$ 0.69
Number of common stock shares issued for services									333,200	76,800
Number of common stock value issued for consulting and investor services									$ 3,332	$ 768
Number of shares issued, value										$ 1,888
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,195,996	871,309
Common stock convertible loans fair value acquired									$ 11,960	$ 8,712
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									21,411
[custom:StockIssuedWithDebtShares]									399,650
[custom:StockIssuedWithDebt]									$ 3,996
Warrants issued for debt settlement
Common stock issuances [Member]
Class of Stock [Line Items]
Shares, Issued									10,000
Accredited Investor [Member]
Class of Stock [Line Items]
Number of restricted stock issued										1,618,704
Number of restricted stock issued during period, value										$ 3,671,311
Stock Options Issuance [Member]
Class of Stock [Line Items]
Stock option issued to employee									24,000
Stock option fair value									$ 49,135
Stock issuances exercise price									$ 2.17
Vesting term									3 years
Contractual term									10 years
Minimum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants and rights outstanding, term									3 years
Warrants exercise price per share									$ 3.50
Maximum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants and rights outstanding, term									5 years
Warrants exercise price per share									$ 5
Series D Registered Direct Offering [Member]
Class of Stock [Line Items]
Warrant to purchase shares of common stock			39,778
Warrants exercise price per share			$ 8.40
Proceeds from Warrant Exercises			$ 140,214
[custom:NumberOfWarrantsExercised]			19,889
Fair value of warrant			$ 186,802
Share-based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance												3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									21,411
Other Plans [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									1,333,101
Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									1,000,000
Convertible preferred stock, par value									$ 0.01
Convertible preferred stock, shares issued									1,000,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									20,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									313,960
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									279,256
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									88,098
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									850	850
Convertible preferred stock, par value								$ 0.01	$ 0.01	$ 0.01
Convertible preferred stock, shares issued									300	300
Sale of stock								843
Preferred Stock, Redemption Amount								$ 1,000
Proceeds from direct offering								$ 843,000
Conversion of stock into shares								84	84
Warrants and rights outstanding, term								5 years
Warrant to purchase shares of common stock								21
Warrants exercise price per share								$ 24.30
Purchase price per units sold								$ 1,000
Stock conversion price per share									$ 19.50
Convertible preferred stock, conversion percentage									300.00%
Average daily trading volume									50,000
Ownership percentage									50.00%
Pro rate basis description									the holders of Series D Convertible Preferred Stock will have the right to participate on a pro-rata basis in up to 50% of such Subsequent Financing
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									500
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									240,000	240,000
Convertible preferred stock, par value							$ 0.01		$ 0.01	$ 0.01
Convertible preferred stock, shares issued									80,570	80,570
Sale of stock							4,844
Proceeds from direct offering							$ 726,600
Warrants and rights outstanding, term							3 years
Warrant to purchase shares of common stock							1
Warrants exercise price per share							$ 15
Purchase price per units sold							$ 150
Convertible preferred stock, conversion percentage									12.00%
Number of common stock shares issued, shares							1
Cumulative dividend rate percentage									4.00%
Percentage of shares purchased for investment									6.00%
Series G Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Proceeds from direct offering									$ 2,500,000
Purchase price per units sold									$ 22.50
Average daily trading volume									334
Investment amount									$ 100,000
Series G Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Investment amount									$ 250,000
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized						10,000			10,000	10,000			10,000
Convertible preferred stock, par value						$ 0.01			$ 0.01	$ 0.01
Convertible preferred stock, shares issued									10,000	10,000
Conversion of stock into shares						4
Purchase price per units sold						$ 24.08
Number of common shares exchanged						33,334
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized				21					21
Convertible preferred stock, par value				$ 0.01
Convertible preferred stock, shares issued				21
Conversion of stock into shares				3,334
Purchase price per units sold				$ 7.50
Number of common shares exchanged				70,000
Common stock, par value				$ 0.01
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									6,250	6,250
Convertible preferred stock, par value					$ 0.01				$ 0.01	$ 0.01
Convertible preferred stock, shares issued									3,458	3,458
Sale of stock					5,087.5
Proceeds from direct offering					$ 2,034,700
Conversion of stock into shares					34				34
Warrant to purchase shares of common stock					34
Warrants exercise price per share					$ 12
Purchase price per units sold					$ 400				$ 24
Average daily trading volume									1,667
Cumulative dividend rate percentage									4.00%
Percentage of shares purchased for investment									6.00%
Series J Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Proceeds from direct offering									$ 2,500,000
Investment amount									250,000
Series J Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Investment amount									$ 250,000
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									15,000	15,000
Convertible preferred stock, par value									$ 0.01	$ 0.01
Convertible preferred stock, shares issued									6,880	6,880
Conversion of stock into shares									34
Purchase price per units sold									$ 24
Average daily trading volume									1,667
Percentage of shares purchased for investment									6.00%
Series K Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Proceeds from direct offering									$ 2,500,000
Investment amount									$ 100,000
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized									10,000	10,000
Convertible preferred stock, par value									$ 0.01	$ 0.01
Convertible preferred stock, shares issued									8,649	8,043
Number of common stock shares issued, shares									82,373
Number of shares issued, value									$ 184,274
Dividend on convertible preferred stock									8.00%	8.00%
Common stock convertible loans fair value acquired									$ 2,989,990
Series AA Convertible Preferred Stock [Member] | Lenders [Member]
Class of Stock [Line Items]
Common stock convertible loans fair value acquired									$ 1,400,000
Series AA Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Accredited Investors [Member]
Class of Stock [Line Items]
Sale of stock									406	60
Warrant to purchase shares of common stock									406,000	60,000
Warrants exercise price per share									$ 3.50	$ 3.50
Common stock, par value									$ 0.01	$ 0.01
Number of preferred stock issued upon conversion									1,000	1,000
Sale of stock, amount									$ 1,015,000	$ 150,000
Series AA Preferred Stock [Member]
Class of Stock [Line Items]
Warrants and rights outstanding, term									5 years	5 years
Warrant to purchase shares of common stock										44,000
Warrants exercise price per share									$ 3.50	$ 3.50
Fair value of warrant									$ 245,635	$ 38,783
Number of common stock shares issued, shares									200	122,135
Number of preferred stock issued upon conversion										44
Number of shares issued upon conversion, value										$ 110,000
Warrant issued									200,100
Number of shares issued, value										299,709
Series AA Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Fair value of warrant									$ 509,130
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Adjusted beneficial conversion feature value for deemed dividend									$ 873,798	$ 61,180

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Sep. 25, 2021	Sep. 25, 2021	Dec. 23, 2020	Sep. 25, 2020	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Debt instrument, description			we are obligated to issue 100,000 warrants if the loan is not repaid before January 23, 2021 and an additional 10,000 shares of common stock and 100,000 warrants if the loan is not repaid before February 23, 2021. We are also obligated to issue 10,000 shares of common stock and 200,000 warrants if the loan is not repaid before March 23, 2021. During the year ended December 31, 2021 the Company issued 400,000 warrants to this lender ($3.50 exercise price and five-year term) with a fair value of $600,298. The Company is also obligated to issue 10,000 shares of common stock to this lender every 31 days up to the loan’s maturity date on June 23, 2021.			Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lesser of $2.50 per share or 90% of the lowest trading price over the previous 20 days. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion
Proceeds from Convertible Debt						$ 5,514,250	$ 8,296,800
Debt Instrument, Term		3 years
Stock Issued During Period, Shares, New Issues						2,883,282
Debt Conversion, Original Debt, Amount						$ 1,705,455
Repayments of Convertible Debt				$ 134,805		1,833,295	$ 2,857,007
Option Indexed to Issuer's Equity, Strike Price		$ 3.50
Repayments of Debt						$ 1,833,295
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	37,000						188,778
Warrant [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Warrants or Options Issued	30,000
Lender [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues						140,200
Debt Conversion, Original Debt, Amount						$ 350,500
Three Loans [Member]
Subsequent Event [Line Items]
Debt instrument face amount						475,000
Five Convertible Loans [Member]
Subsequent Event [Line Items]
Debt instrument face amount						$ 1,045,000
Merchant Agreements [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Repayments of Debt	$ 107,000
Merchant Agreements [Member] | Minimum [Member]
Subsequent Event [Line Items]
Debt, interest rate						9.30%
Merchant Agreements [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt, interest rate						14.00%
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from loans					$ 145,487
Debt, interest rate					12.00%
Debt default description					One loan is convertible at $2.50 per share other than in an event of default otherwise upon an event of default, the conversion price will be at 75% of the lowest trading price for the common stock over five days before conversion. The other loan is convertible, upon an event of default, at 75% of the lowest trading price for the common stock over five days before conversion.
Debt Instrument, Convertible, Conversion Price					$ 2.50
Original issue discount percentage					10.00%
Debt instrument, description					In this time the Company also rolled over two loans totaling $475,000 (dated June 30, 2021, and June 28, 2021) into new loans totaling $1,200,000 with terms extended six to eight months. The Company issued 132,000 shares of common stock as origination fees for the new loans. Separately, during this period the Company extended five loans totaling $1,045,000 (dated July 16, 2021, June 30,2021, July 16, 2021, July 16, 2021 and July 16, 2021) for five to six months with new principal of $1,095,250 issuing 147,500 shares of common stock as extension fees.
Subsequent Event [Member] | Three Loans [Member]
Subsequent Event [Line Items]
Debt instrument face amount					$ 1,200,000
[custom:StockIssuedDuringPeriodSharesNewIssuesForOriginationFee]					132,000
Subsequent Event [Member] | Three Loans [Member] | Minimum [Member]
Subsequent Event [Line Items]
Debt Instrument, Term					6 months
Subsequent Event [Member] | Three Loans [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt Instrument, Term					8 months
Subsequent Event [Member] | Five Convertible Loans [Member]
Subsequent Event [Line Items]
[custom:CommonStockForInterestAndExtensionFees]					$ 1,095,250
[custom:StockIssuedDuringPeriodSharesNewIssuesForExtensionFee]					147,500
Subsequent Event [Member] | Five Convertible Loans [Member] | Minimum [Member]
Subsequent Event [Line Items]
Debt Instrument, Term					5 months
Subsequent Event [Member] | Five Convertible Loans [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt Instrument, Term					6 months
Subsequent Event [Member] | Merchant Agreements [Member]
Subsequent Event [Line Items]
Debt instrument, description					Merchant Cash lender agreements (collecting $361,120 and obligating the Company to pay $18,990 each week to the lenders
Subsequent Event [Member] | Merchant Cash Lender Agreements [Member]
Subsequent Event [Line Items]
Proceeds from Convertible Debt					$ 361,120
Subsequent Event [Member] | Convertible Debt [Member]
Subsequent Event [Line Items]
Related Party Transaction, Due from (to) Related Party, Current					177,500
Obligating to pay week to the lenders					$ 18,990